# Chapter 112: Sedative, Hypnotic, or Anxiolytic Use Disorder

# Chapter 12: The Biological and Neurological Basis of Sedative, Hypnotic, or Anxiolytic Use Disorder

## Introduction

Sedative, Hypnotic, or Anxiolytic Use Disorder represents a complex and often debilitating condition characterized by a maladaptive pattern of substance use leading to clinically significant impairment or distress (Franklin, 1995). This class of substances includes a wide range of central nervous system (CNS) depressants, such as benzodiazepines, barbiturates, and related hypnotic agents (z-drugs), which are prescribed therapeutically for conditions like anxiety and insomnia (Fingerhood, 2020; Elhassan et al., 2018). However, their potential for misuse, abuse, and dependence presents a significant public health problem (Rao & Sathyanarayana Rao, 2008; Culberson & Ziska, 2008; O’Brien, 2005). Understanding this disorder from a biological and neurological perspective is crucial for developing effective prevention and treatment strategies. The progression from therapeutic use or occasional misuse to a compulsive, addictive pattern of behavior is underpinned by profound changes in brain structure, function, and neurochemistry (Sussman, 2025; Koob, 2020).

The diagnostic framework for substance dependence, as outlined in criteria such as the *Diagnostic and Statistical Manual of Mental Disorders* (*DSM*), emphasizes a cluster of cognitive, behavioral, and physiological symptoms (Franklin, 1995; Takahashi & Franklin, 1996). Key features include the development of tolerance, where increasing doses are needed to achieve the desired effect, and the emergence of a withdrawal syndrome upon cessation or reduction of use (Franklin, 1995; Hayes & Lingford‐Hughes, 2023). Other criteria highlight the loss of control over substance intake, a persistent desire or unsuccessful efforts to cut down, and continued use despite awareness of adverse physical or psychological consequences (Franklin, 1995; Perera-Diltz, 2015). These clinical manifestations are the outward expression of deep-seated neuroadaptations within the brain's reward, stress, and executive function circuits (Koob, 2014; Koob, 2020).

Sedative, hypnotic, or anxiolytic agents primarily exert their effects by enhancing the activity of the gamma-aminobutyric acid (GABA) system, the principal inhibitory neurotransmitter system in the CNS (Tseng et al., 2020; Elhassan et al., 2018). This action leads to the desired effects of sedation, anxiolysis, and hypnosis (McCann, 1949; Fingerhood, 2020). However, chronic exposure to these substances triggers a cascade of compensatory changes in the brain. These neuroadaptations attempt to counteract the drug's persistent inhibitory influence, leading to a state of hyperexcitability that becomes manifest during withdrawal (Duncan, 1988; Yersin, 1999). This withdrawal state is characterized by symptoms that are often the opposite of the drug's effects, including anxiety, agitation, insomnia, and in severe cases, seizures and psychosis (Pétursson, 1994; Bismuth et al., 1980; Fialip et al., 1987).

This chapter will provide a comprehensive overview of the biological and neurological underpinnings of Sedative, Hypnotic, or Anxiolytic Use Disorder. It will explore the primary neurotransmitter systems involved, the neural circuits that are dysregulated, and the genetic and molecular factors that may confer vulnerability. Furthermore, it will examine the cellular and synaptic mechanisms of tolerance and dependence, review findings from neuroimaging studies, and discuss the developmental aspects that contribute to the disorder's emergence. Finally, the chapter will connect these biological mechanisms to treatment implications, highlighting how an understanding of the underlying neurobiology can inform more effective therapeutic interventions. This exploration is essential, as the disorder is not merely a behavioral issue but a chronic, relapsing brain disease rooted in fundamental neurobiological processes (Clay et al., 2008; Koob, 2020).

## Neurobiological Systems

The development and maintenance of Sedative, Hypnotic, or Anxiolytic Use Disorder are critically linked to the dysregulation of several key neurobiological systems. The primary mechanism of action for most of these drugs involves the potentiation of GABAergic neurotransmission, but the chronic nature of the disorder implicates broader neuroadaptations in reward, stress, and executive control circuits (Koob, 2020; Batinić et al., 2017).

### The GABAergic System: The Primary Target

The gamma-aminobutyric acid (GABA) system is the main inhibitory neurotransmitter system in the central nervous system, playing a crucial role in reducing neuronal excitability (Tseng et al., 2020). Most sedative, hypnotic, and anxiolytic drugs, particularly benzodiazepines and barbiturates, are positive allosteric modulators of the GABA-A receptor (Elhassan et al., 2018; Tseng et al., 2020). This receptor is a ligand-gated ion channel complex that, upon binding with GABA, allows chloride ions to enter the neuron, leading to hyperpolarization and making it less likely to fire an action potential (Hertz et al., 2014). Benzodiazepines bind to a specific site on the GABA-A receptor, increasing the frequency of channel opening in the presence of GABA, thereby enhancing its inhibitory effect (Tseng et al., 2020). This enhanced inhibition produces the characteristic sedative, anxiolytic, and hypnotic effects of these drugs (Fingerhood, 2020; McCann, 1949).

Chronic exposure to these agents leads to significant neuroadaptive changes in the GABAergic system. The brain attempts to restore homeostasis by downregulating GABA-A receptor function, which can involve changes in receptor density, subunit composition, and allosteric coupling (Reeves & Kamal, 2019; Wright, 2020). This neuroadaptation is the basis for tolerance, where higher doses of the drug are required to produce the same physiological effect (Hayes & Lingford‐Hughes, 2023; Franklin, 1995). Upon abrupt cessation or dose reduction, the system is left in a state of diminished GABAergic inhibition and resultant CNS hyperexcitability (Duncan, 1988). This hyperexcitable state manifests clinically as the withdrawal syndrome, characterized by symptoms such as anxiety, agitation, insomnia, restlessness, and in severe cases, seizures and delirium (Pétursson, 1994; Bismuth et al., 1980; Fialip et al., 1987; Yersin, 1999). The severity and time course of withdrawal are influenced by the drug's elimination half-life; drugs with shorter half-lives, like alprazolam and lorazepam, tend to produce more severe and immediate withdrawal reactions compared to longer-acting agents like diazepam (Wolf & Griffiths, 1991; Kales et al., 1983).

### The Dopaminergic Reward System: Reinforcement and Craving

While GABA is the primary target, the addictive potential of sedatives is also mediated through their interaction with the brain's reward circuitry, particularly the mesolimbic dopamine system (Koob, 2020; Wise, 1982). This pathway, originating in the ventral tegmental area (VTA) and projecting to the nucleus accumbens (NAc) and prefrontal cortex, is central to processing reward, motivation, and reinforcement for all drugs of abuse (Dhillon, 2013; Kalivas et al., 2003). Sedatives are thought to increase dopamine release in the NAc indirectly by inhibiting GABAergic interneurons in the VTA, which in turn disinhibits dopamine neurons (Batinić et al., 2017; Koob, 2020). This increase in dopamine activity produces feelings of pleasure or euphoria and reinforces drug-taking behavior (Hayes & Lingford‐Hughes, 2023; Sanchis‐Segura & Spanagel, 2006).

With chronic use, neuroadaptations occur within this reward system, leading to a "reward deficit state" during withdrawal (Koob, 2014; Koob, 2020). This state is characterized by a blunted dopamine response to both the drug and natural rewards, contributing to the anhedonia and dysphoria experienced during abstinence (Wise, 1982). This negative emotional state becomes a powerful motivator for continued drug use, shifting the driver of addiction from positive reinforcement (seeking a "high") to negative reinforcement (seeking relief from a negative state) (Koob, 2020; Yi & 郝伟, 2004). The process of associative learning links environmental cues with drug use, and these cues can trigger intense craving and drug-seeking behavior, a key component of relapse (Franken & Wiers, 2013; Stewart, 2003).

### Stress and Anti-Stress Systems: The Negative Reinforcement Loop

The development of sedative use disorder involves a profound dysregulation of the brain's stress systems, which contributes significantly to the negative reinforcement cycle (Koob, 2020; Vendruscolo & Koob, 2019). Acute drug use can temporarily alleviate feelings of stress and anxiety, which is a primary reason for their therapeutic use and misuse (Batinić et al., 2017; Maier & Schaub, 2015). However, chronic use and subsequent withdrawal lead to a "stress surfeit" state, or hyperkatifeia, characterized by a heightened negative emotional response (Koob, 2020). This is mediated by the sensitization of stress neurocircuits, particularly those involving the extended amygdala and the release of stress-related neuropeptides like corticotropin-releasing factor (CRF) (Koob, 2020; McEwen, 1998).

During withdrawal, increased activity in the extended amygdala and elevated levels of CRF contribute to the anxiety, irritability, and dysphoria that drive compulsive drug-seeking (Koob, 2020). This process reflects an allostatic shift in the brain, where the baseline hedonic state is lowered, and the individual requires the drug simply to feel "normal" rather than to experience pleasure (Koob, 2014). This chronic state of stress and negative affect is a major factor in relapse, as individuals are motivated to use the substance to escape these aversive feelings (Stewart, 2003; Vendruscolo & Koob, 2019). The interaction between stress and addiction is bidirectional; stress can precipitate relapse to drug-seeking (Stewart, 2003), and the addiction cycle itself constitutes a chronic stressor that further dysregulates these systems (House, 1987; Plaut & Friedman, 1982).

### Glutamate and Excitatory Neurotransmission

While sedatives enhance inhibition, the brain's primary excitatory neurotransmitter, glutamate, also plays a crucial role in the neurobiology of sedative use disorder (Batinić et al., 2017). During chronic sedative use, the brain compensates for the persistent GABAergic enhancement by upregulating the activity of the glutamatergic system, particularly N-methyl-D-aspartate (NMDA) receptors (Collo & Pich, 2018). This upregulation contributes to the state of neuronal hyperexcitability seen during withdrawal (Duncan, 1988). The excessive glutamate release during withdrawal can be excitotoxic, potentially contributing to neuronal damage and the severity of withdrawal symptoms, including seizures (Pujol & Puel, 1999; Yersin, 1999). Furthermore, glutamate is integral to the neuroplasticity underlying learning and memory, and its dysregulation is implicated in the consolidation of drug-related memories and cue-induced craving that drive relapse (Kalivas et al., 2003; Stewart, 2003). Interventions targeting the glutamatergic system, such as NMDA receptor antagonists like ketamine, are being explored for their potential to disrupt these maladaptive memories and treat addictive disorders (Collo & Pich, 2018; Andrade, 2017).

## Genetic and Molecular Basis

The development of Sedative, Hypnotic, or Anxiolytic Use Disorder is not solely a consequence of environmental exposure; there is a significant contribution from genetic and molecular factors that create individual differences in vulnerability (Sussman, 2025; Winters & Ingwalson, 2022). These factors can influence initial sensitivity to the drugs, the rate at which tolerance and dependence develop, the severity of withdrawal symptoms, and the propensity for relapse.

### Heritability and Genetic Predisposition

Addictive disorders, in general, are recognized as having a strong genetic component (Sussman, 2025; Daley & Douaihy, 2019). Family, twin, and adoption studies have consistently shown that vulnerability to substance use disorders is heritable (Cadoret & Winokur, 1972; Winters & Ingwalson, 2022). While specific heritability estimates for sedative use disorder are less established than for alcohol or opioid use disorders, the shared neurobiological pathways suggest a similar pattern of genetic influence (Maremmani et al., 2010). Genetic factors may account for a substantial portion of the variance in risk, influencing personality traits such as impulsivity and novelty seeking, which are themselves associated with a higher likelihood of substance misuse (Voon et al., 2007; Batinić et al., 2017).

A family history of substance use disorders, particularly alcoholism, is a significant risk factor, suggesting a shared genetic predisposition across different classes of CNS depressants (Cadoret & Winokur, 1972; Maremmani et al., 2010). This vulnerability may be polygenic, involving multiple genes that each contribute a small amount to the overall risk (Padmos, 2009). These genes are likely involved in the regulation of the key neurotransmitter systems implicated in addiction, including the GABAergic, dopaminergic, and stress response systems (Koob, 2020; Hertz et al., 2014).

### Candidate Genes and Molecular Mechanisms

Research has begun to identify specific candidate genes that may mediate the risk for sedative dependence. A primary area of focus is the genes encoding subunits of the GABA-A receptor, the direct target of benzodiazepines and barbiturates (Tseng et al., 2020). The GABA-A receptor is a pentameric complex composed of various subunits (e.g., α, β, γ), and the specific combination of these subunits determines the receptor's pharmacological properties, including its affinity for benzodiazepines (Elhassan et al., 2018; Anderson, 2010). Polymorphisms in the genes for these subunits could alter an individual's response to sedative drugs, influencing both their therapeutic and rewarding effects, as well as the rate of neuroadaptation that leads to tolerance and dependence (Wolf & Griffiths, 1991).

The dopaminergic system is another critical area for genetic investigation. Genes related to dopamine receptors (e.g., DRD2), transporters (DAT), and metabolic enzymes are all plausible candidates for influencing addiction vulnerability (Wise, 1982; Huang & Tsai, 2012). For instance, variations in the DRD2 gene have been associated with altered reward sensitivity and an increased risk for various addictive behaviors (Huang & Tsai, 2012). These genetic differences may contribute to how reinforcing an individual finds the dopamine-releasing effects of sedatives, thereby influencing the likelihood of transitioning from use to misuse (Dhillon, 2013).

Furthermore, genes involved in drug metabolism can play a significant role. The cytochrome P450 (CYP) family of enzymes is responsible for metabolizing many sedative and hypnotic drugs (Grannell, 2020; Shah, 2005). Genetic polymorphisms in CYP enzymes can lead to significant inter-individual variability in drug clearance, resulting in some individuals being "slow" or "rapid" metabolizers (Andrade, 2012). Slow metabolizers may experience higher drug concentrations and more pronounced sedative effects from standard doses, increasing the risk of toxicity and adverse events, while rapid metabolizers might experience reduced efficacy, potentially leading to dose escalation (Shah, 2005; Hansen & Schneiweiss, 1981).

### Neuroplasticity, Gene Expression, and Epigenetics

Chronic drug exposure induces lasting changes in the brain through mechanisms of neuroplasticity, which involve alterations in gene expression (Kalivas et al., 2003; Robertson et al., 2019). Repeated use of sedatives triggers a cascade of intracellular signaling pathways that ultimately alter the transcription of numerous genes (Hertz et al., 2014). This process is mediated by transcription factors such as CREB (cAMP response element-binding protein) and ΔFosB (Kalivas et al., 2003; Antonio & Alfredo, 2012).

Chronic drug use leads to the accumulation of ΔFosB, a highly stable transcription factor that persists for weeks or months after drug cessation (Kalivas et al., 2003). This accumulation is thought to be a key molecular switch that mediates long-term neuroplastic changes, contributing to a state of heightened vulnerability to relapse (Kalivas et al., 2003). ΔFosB influences the expression of genes involved in synaptic structure and function, thereby strengthening the neural circuits associated with drug-seeking and compulsive behavior (Kalivas et al., 2003; Antonio & Alfredo, 2012).

Epigenetic mechanisms, such as DNA methylation and histone acetylation, are also emerging as critical players in the molecular basis of addiction (Sussman, 2025). These processes regulate gene expression without altering the DNA sequence itself and can be influenced by environmental factors, including drug exposure and stress (Meyer & Hamel, 2014). Chronic sedative use can induce epigenetic modifications that lead to enduring changes in the expression of genes related to synaptic plasticity, stress reactivity, and reward processing (Sussman, 2025). Such epigenetic marks may explain how early life stress or trauma can increase vulnerability to addiction later in life and how the effects of chronic drug use can persist long after the substance has been cleared from the body (Meyer & Hamel, 2014; van der Kolk, 1998). These molecular scars contribute to the chronic, relapsing nature of the disorder (Kalivas et al., 2003).

## Brain Structure and Function

Sedative, Hypnotic, or Anxiolytic Use Disorder is associated with significant alterations in both the structure and function of the brain. These changes are not merely consequences of the disorder but are integral to its pathophysiology, driving the transition from controlled use to compulsive drug-seeking and contributing to the cognitive and emotional impairments observed in affected individuals. Neuroimaging studies, though less extensive for sedatives compared to other substances like alcohol or cocaine, provide valuable insights into the neural circuits that are dysregulated.

### Key Brain Regions and Neural Circuits

The neurocircuitry of addiction involves a complex interplay between three major brain systems: the basal ganglia, the extended amygdala, and the prefrontal cortex (Koob, 2020; Koob, 2014).

1.  **The Basal Ganglia and Reward Circuitry:** This system, which includes the nucleus accumbens (NAc), is central to the binge/intoxication stage of addiction (Koob, 2020). As discussed previously, sedatives increase dopamine in the NAc, which reinforces drug-taking behavior (Wise, 1982; Dhillon, 2013). Chronic use leads to neuroadaptations that blunt the reward response, creating a reward deficit state (Koob, 2014). Functionally, this manifests as anhedonia—a reduced ability to experience pleasure from natural rewards—which is a core feature of withdrawal and a driver of continued drug use (Barch et al., 2019; Wise, 1982). The basal ganglia are also involved in habit formation, and with repeated drug use, drug-seeking behavior becomes increasingly automatic and compulsive, shifting from goal-directed action to a stimulus-response habit (Batinić et al., 2017).

2.  **The Extended Amygdala and Stress Circuitry:** Comprising structures like the central nucleus of the amygdala and the bed nucleus of the stria terminalis, the extended amygdala is critical for the withdrawal/negative affect stage (Koob, 2020). This system mediates the brain's response to stress. In sedative use disorder, this circuit becomes sensitized, leading to a hyperactive stress response and a negative emotional state (hyperkatifeia) during abstinence (Koob, 2020; Vendruscolo & Koob, 2019). This heightened state of anxiety, irritability, and dysphoria provides a powerful negative reinforcement signal, compelling the individual to seek the drug to alleviate this distress (Yi & 郝伟, 2004; Koob, 2020). Functional imaging might reveal hyperactivity in the amygdala in response to stress or drug cues in abstinent individuals.

3.  **The Prefrontal Cortex (PFC) and Executive Function:** The PFC, particularly regions like the orbitofrontal and anterior cingulate cortex, is responsible for executive functions, including decision-making, impulse control, and assigning salience to stimuli (Batinić et al., 2017; Huang & Tsai, 2012). This system is central to the preoccupation/anticipation or craving stage of addiction (Koob, 2020). In sedative use disorder, PFC function is compromised, leading to impaired judgment, increased impulsivity, and an overvaluation of drug-related cues at the expense of other life goals (Huang & Tsai, 2012; Batinić et al., 2017). This executive dysfunction makes it difficult for individuals to resist cravings and make rational decisions to abstain from drug use (Franken & Wiers, 2013). Reduced activity in the frontal lobes has been linked to impulse control disorders, whereas increased activity may be associated with compulsive disorders (Batinić et al., 2017).

### Neuroimaging Findings

While specific neuroimaging research on sedative use disorder is limited in the provided sources, findings from studies on other substance use disorders and related conditions can be extrapolated to suggest likely structural and functional changes.

**Structural Changes:** Chronic substance use, particularly with CNS depressants like alcohol, is associated with structural brain changes, including brain atrophy and ventricular enlargement (Dodd, 2007). While the evidence for such gross changes with benzodiazepines is less clear, long-term use may contribute to more subtle alterations in gray and white matter integrity, particularly in the frontal lobes and limbic regions (Batinić et al., 2017; Jellinger, 2025). These structural deficits could underlie some of the persistent cognitive impairments seen in long-term users.

**Functional Changes:** Functional neuroimaging techniques, such as functional magnetic resonance imaging (fMRI) and positron emission tomography (PET), have been instrumental in mapping the addicted brain. In substance use disorders, these studies typically show:
*   **Hyperreactivity to Drug Cues:** Brain regions involved in reward and motivation, such as the NAc and amygdala, show exaggerated activation when individuals are exposed to drug-related cues (Franken & Wiers, 2013). This heightened neural response is thought to be the substrate of craving.
*   **Hypoactivation During Executive Tasks:** During tasks that require cognitive control and decision-making, individuals with addiction often show reduced activation in prefrontal cortex regions (Batinić et al., 2017; Huang & Tsai, 2012). This hypofrontality reflects the executive dysfunction that contributes to loss of control over drug use.
*   **Altered Resting-State Connectivity:** Even in the absence of a specific task, the brains of individuals with addiction show altered patterns of functional connectivity. There may be weakened connectivity within executive control networks and strengthened connectivity within networks involved in habit and reward, reflecting a brain that is biased toward compulsive drug-seeking (Chen & Gong, 2021).

### Cognitive and Behavioral Correlates

The structural and functional brain changes associated with sedative use disorder manifest as a range of cognitive and behavioral impairments. Chronic use of sedatives, particularly benzodiazepines, is well-known to cause cognitive side effects, including impairments in memory, attention, and processing speed (Dhingra et al., 2015; Erman, 2006; Verster et al., 2007). These effects can be particularly pronounced in older adults, increasing the risk of confusion, falls, and accidents (Hong & Bishop, 2014; Elhassan et al., 2018).

*   **Memory Impairment:** Sedatives can cause anterograde amnesia, which is a difficulty in forming new memories (Streufert et al., 1996; Kales & Kales, 1983). While this can be a therapeutic goal for procedural sedation, it is a significant adverse effect in chronic users, impacting daily functioning (Dhingra et al., 2015). The effects on long-term memory are less clear but may be compromised by chronic use (Marcus & Plasky, 1988).
*   **Psychomotor Impairment:** Sedation, drowsiness, ataxia, and slowed reaction time are common effects that impair psychomotor performance (Wilson, 1985; Dhingra et al., 2015). This significantly increases the risk of accidents, particularly when driving or operating machinery (Schenck, 2003; Wilson, 1985).
*   **Executive Dysfunction:** As a result of PFC disruption, individuals may exhibit poor judgment, impulsivity, and difficulty with planning and organization (Huang & Tsai, 2012; Batinić et al., 2017). This cognitive impairment not only is a consequence of the disorder but also perpetuates it by undermining the capacity for self-control and recovery-oriented decision-making (Franken & Wiers, 2013).

These cognitive deficits can persist even after cessation of the drug, although the extent of reversibility is debated and may depend on the duration and intensity of use, as well as individual factors (Ownby, 2006). The persistent cognitive changes highlight that sedative use disorder is not simply a behavioral pattern but a condition involving lasting changes to brain function.

## Developmental Neurobiology

The trajectory of Sedative, Hypnotic, or Anxiolytic Use Disorder is significantly influenced by developmental factors, with adolescence and early adulthood representing a critical period of vulnerability (McGorry et al., 2011; Girolamo et al., 2011). The neurobiological processes occurring during this life stage, combined with psychosocial pressures, create a fertile ground for the initiation of substance use and the rapid progression to a use disorder (Winters & Ingwalson, 2022).

### Adolescent Vulnerability

Adolescence is a period of profound brain maturation, particularly in the prefrontal cortex (PFC), which is responsible for executive functions like impulse control, decision-making, and risk assessment (Martı́nez-Raga & López-Cerveró, 2019). This region does not fully mature until the mid-20s (Winters & Ingwalson, 2022). Simultaneously, the brain's reward and emotional processing circuits, including the limbic system, are highly active and sensitive during this period (Sussman, 2025). This developmental mismatch—an underdeveloped "braking" system (PFC) and a highly sensitive "accelerator" system (limbic reward circuits)—contributes to the characteristic adolescent behaviors of risk-taking, sensation-seeking, and heightened sensitivity to peer influence (Martı́nez-Raga & López-Cerveró, 2019; Hechtman, 1991).

This neurodevelopmental context makes adolescents particularly vulnerable to experimenting with substances, including sedatives (Takahashi & Franklin, 1996). The anxiolytic and euphoric effects of these drugs can be highly reinforcing in the context of adolescent social anxieties, academic pressures, and emotional lability (Zauner, 1978; Catheline, 2005). Furthermore, the adolescent brain appears to be more sensitive to the neuroplastic changes induced by drugs, potentially leading to a more rapid development of tolerance and dependence (Winters & Ingwalson, 2022). Early onset of substance use is a robust predictor of developing a severe, chronic substance use disorder in adulthood (McGorry et al., 2011; Hechtman, 1991).

### Comorbidity with Other Neurodevelopmental and Psychiatric Disorders

The risk of developing a sedative use disorder is amplified by the presence of comorbid neurodevelopmental or psychiatric conditions that often emerge during childhood and adolescence (McGorry et al., 2011).

*   **Attention-Deficit/Hyperactivity Disorder (ADHD):** ADHD is characterized by core symptoms of inattention, hyperactivity, and impulsivity (Schweitzer, 2010; Yan, 2024; Anis et al., 2025). The inherent impulsivity and difficulties with self-regulation in ADHD are significant risk factors for substance use initiation and the development of a use disorder (Martı́nez-Raga & López-Cerveró, 2019; Nigg, 2003). Individuals with ADHD may misuse sedatives to self-medicate feelings of restlessness or to counteract the side effects of stimulant medications, such as insomnia (Breggin, 1999; Kim, 2019). The co-occurrence of ADHD and substance use disorders is common and is associated with a poorer prognosis for both conditions (Hechtman, 1991; Martı́nez-Raga & López-Cerveró, 2019).

*   **Anxiety and Mood Disorders:** Anxiety and depressive disorders frequently have their onset during adolescence (Girolamo et al., 2011; Hatcher-Kay & King, 2003). Sedatives and anxiolytics are often prescribed for these conditions, creating a direct pathway for exposure (Greydanus et al., 2008). Adolescents may begin to misuse their prescribed medication to cope with overwhelming anxiety or low mood, leading to a cycle of dependence (Sussman & Ames, 2008). The relationship is often bidirectional, as chronic sedative use and withdrawal can themselves induce or exacerbate anxiety and depressive symptoms (Nijdam, 1990; Wright, 2020; Gallo & Hulse, 2022).

*   **Conduct and Oppositional Defiant Disorders:** These disorders, characterized by aggressive, noncompliant, and antisocial behaviors, are strongly associated with early substance use (Gottlieb & Friedman, 1991; Scott & Palmer, 2020). The behavioral disinhibition central to these conditions lowers the threshold for engaging in risky behaviors, including drug misuse (Nigg, 2003).

### The Role of Early Life Stress and Trauma

Exposure to trauma, abuse, or neglect during childhood and adolescence is a potent risk factor for the development of both psychiatric disorders and substance use disorders (van der Kolk, 1998; Meyer & Hamel, 2014). Early life stress can lead to long-lasting changes in the neurobiology of the stress and reward systems, including dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis and sensitization of limbic circuits (Stratakis et al., 1995; Meyer & Hamel, 2014). These neurobiological alterations create a vulnerability to using substances like sedatives as a form of self-medication to numb emotional pain and regulate a hyper-aroused state (van der Kolk, 1998; Young, 1990). The experience of trauma can lead to a host of psychiatric symptoms, including anxiety, depression, dissociation, and sleep disturbances, all of which may be targeted by sedative misuse (Bolton et al., 2004; Madrid et al., 2006; van der Kolk, 1998). Thus, a history of developmental trauma is a critical factor to consider in the etiology and treatment of sedative use disorder (Young, 1990).

The developmental timing of drug exposure is critical. The brain is undergoing sensitive or critical periods of development where it is particularly susceptible to environmental insults, including drugs (Petruševičienė & Kriščiūnas, 2003). Substance use during these periods can disrupt normal neurodevelopmental trajectories, leading to more severe and persistent cognitive and behavioral deficits later in life (Winters & Ingwalson, 2022). This highlights the importance of prevention and early intervention strategies targeted at youth to mitigate the long-term consequences of sedative misuse (McGorry et al., 2011).

## Treatment Mechanisms

The biological basis of treatment for Sedative, Hypnotic, or Anxiolytic Use Disorder is aimed at managing the acute withdrawal syndrome, preventing relapse, and addressing the underlying neuroadaptations that sustain the disorder. Interventions range from pharmacological strategies that directly target the affected neurotransmitter systems to psychosocial approaches that help patients manage cravings and develop coping skills.

### Pharmacological Management of Withdrawal

The immediate goal of treatment is the safe management of withdrawal, which can be a medical emergency due to the risk of seizures, delirium, and autonomic instability (Yersin, 1999; Bismuth et al., 1980; Tiglao et al., 2021). The cornerstone of withdrawal management is a gradual tapering of the sedative agent or substitution with a long-acting benzodiazepine followed by a slow taper (Ogbonna & Lembke, 2017; Landry et al., 1992).

*   **Benzodiazepine Tapering:** The biological rationale for this approach is to maintain a stable level of GABA-A receptor stimulation to prevent the severe CNS hyperexcitability that characterizes abrupt withdrawal (Pétursson, 1994; Wright, 2020). Substituting a short-acting agent (e.g., alprazolam) with a long-acting one (e.g., diazepam, chlordiazepoxide) provides a smoother and more stable plasma concentration, making the taper more tolerable and reducing the risk of inter-dose rebound symptoms (Wolf & Griffiths, 1991; Erstad & Cotugno, 1995). The taper should be gradual, often over a period of months or even years for long-term users, to allow the GABAergic system to gradually re-equilibrate (Ogbonna & Lembke, 2017; Unknown, 2024). A hyperbolic tapering schedule, where dose decrements become smaller as the total dose gets lower, has been proposed to reflect the nonlinear relationship between dose and receptor occupancy, potentially minimizing withdrawal effects at lower doses (Unknown, 2024; Gallo & Hulse, 2022).

*   **Adjunctive Medications:** Other medications can be used to manage specific withdrawal symptoms. Carbamazepine and gabapentin, which are anticonvulsants, may help reduce withdrawal severity and prevent seizures, potentially by modulating glutamate activity or other mechanisms (Tiglao et al., 2021; Söderpalm, 2002). Beta-blockers like propranolol can be used to manage autonomic hyperactivity symptoms such as tachycardia and tremor (Erstad & Cotugno, 1995; Holloman & Marder, 1997). In cases of severe withdrawal delirium, antipsychotic medications may be required, although caution is needed due to their potential to lower the seizure threshold (Kaggwa et al., 2021; Monotti, 1993).

### Relapse Prevention Pharmacotherapy

Unlike opioid or alcohol use disorders, there are currently no FDA-approved medications specifically for the long-term relapse prevention of sedative use disorder (Rao & Sathyanarayana Rao, 2008). Treatment largely focuses on managing comorbid psychiatric conditions that may drive relapse, such as anxiety and depressive disorders (Rao & Sathyanarayana Rao, 2008; Maremmani et al., 2010).

*   **Antidepressants:** Selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs) are often used to treat underlying anxiety or depression (Baldwin, 2006; Montgomery, 2006). By stabilizing mood and reducing anxiety, these medications can decrease the "need" or motivation to self-medicate with sedatives (Cocchi & Tornati, 1977). However, it is important to note that some antidepressants can themselves cause withdrawal symptoms upon discontinuation, which can be confused with a relapse of the primary disorder (Rosenbaum & Zajecka, 1997; Guy et al., 2020).

*   **Anticonvulsants/Mood Stabilizers:** Medications like valproate have been explored for their potential to reduce craving and impulsivity in substance use disorders, possibly by stabilizing neuronal membranes and modulating both GABA and glutamate systems (Maremmani et al., 2010; Söderpalm, 2002). Their utility in sedative use disorder specifically requires more research.

*   **Novel Agents:** Flumazenil, a benzodiazepine receptor antagonist, has been investigated for its potential to reverse benzodiazepine tolerance and alleviate persistent withdrawal symptoms, possibly by "resetting" GABA-A receptors, though its short duration of action and need for intravenous administration limit its practical use (Lader & Morton, 1992).

### Biological Basis of Psychosocial Interventions

Psychosocial treatments are essential components of a comprehensive care plan and have biological underpinnings, as they can induce neuroplastic changes and help patients gain cognitive control over maladaptive behaviors (Franken & Wiers, 2013).

*   **Cognitive Behavioral Therapy (CBT):** CBT helps patients identify and modify the maladaptive thoughts and behaviors that perpetuate substance use (Gregorowski et al., 2013). For insomnia, a common reason for hypnotic use, CBT-I is a first-line treatment that addresses dysfunctional beliefs about sleep and implements behavioral strategies like stimulus control and sleep restriction, which can restore normal sleep architecture without medication (Matheson et al., 2024; Edinger & Carney, 2008). From a neurobiological perspective, these techniques help reduce the cognitive and physiological hyperarousal that maintains insomnia (Pejović-Nikolić, 2011).

*   **Motivational Enhancement Therapy (MET):** This approach aims to resolve ambivalence about changing substance use behavior (Rao & Sathyanarayana Rao, 2008). By strengthening intrinsic motivation, MET engages the brain's prefrontal executive control circuits, enhancing the individual's capacity to override impulsive drives from subcortical reward regions (Franken & Wiers, 2013).

*   **Stress Management and Relaxation Techniques:** Given the strong link between stress and relapse, interventions that teach stress management, such as mindfulness and relaxation exercises, are crucial (Stewart, 2003; Plaut & Friedman, 1982). These techniques can help down-regulate the hyperactive stress response systems (e.g., HPA axis, sympathetic nervous system) that are sensitized by chronic drug use, thereby reducing the urge to use sedatives to cope with stress (Wiegant, 1991; Sandi, 2013).

Ultimately, effective treatment integrates these approaches, using pharmacotherapy to stabilize the acute biological crisis of withdrawal and psychosocial interventions to promote long-term changes in brain function and behavior, leading to sustained recovery (Daley & Douaihy, 2006).

## Future Directions

While our understanding of the biological basis of Sedative, Hypnotic, or Anxiolytic Use Disorder has advanced significantly, numerous questions remain unanswered, and several promising avenues for future research are emerging. The complexity of the disorder, involving multiple interacting neurobiological systems, necessitates a more nuanced and personalized approach to both research and treatment.

### Refining Neurobiological Models

The current models of addiction, which emphasize the interplay of reward deficit, stress surfeit, and executive dysfunction, provide a robust framework (Koob, 2020; Koob, 2014). However, future research must refine these models specifically for sedative-hypnotics. While these drugs engage the common reward pathway, their primary action on the GABA system distinguishes them from stimulants or opioids (Tseng et al., 2020). Future studies should investigate how chronic potentiation of GABAergic inhibition uniquely alters the long-term function and connectivity of reward and stress circuits. For example, does the brain's adaptation to chronic sedation lead to different patterns of prefrontal cortex dysfunction compared to adaptation to chronic stimulation? Answering such questions will require more longitudinal neuroimaging studies that track individuals from initial use through the development of dependence and into abstinence, mapping the precise trajectory of structural and functional brain changes (Jablensky, 2012).

### Genomics and Personalized Medicine

The identification of genetic risk factors for sedative use disorder is still in its early stages (Sussman, 2025). Large-scale genome-wide association studies (GWAS) are needed to identify novel genetic variants associated with vulnerability. Beyond simply identifying risk alleles, future research should focus on gene-environment interactions (Meyer & Hamel, 2014). For example, how do specific genetic polymorphisms related to GABA-A receptor subunits or stress-response systems interact with early life trauma or chronic stress to increase the risk of developing the disorder (van der Kolk, 1998)? Understanding these interactions could lead to the development of genetic screening tools to identify high-risk individuals who should be prescribed sedatives with extreme caution (Winters & Ingwalson, 2022). Furthermore, pharmacogenomic research could help predict individual responses to both sedative drugs and potential anti-addiction medications, paving the way for personalized treatment strategies that maximize efficacy and minimize adverse effects (Shah, 2005; Andrade, 2012).

### Novel Pharmacotherapeutic Targets

The lack of approved long-term pharmacotherapies for sedative use disorder is a major gap in clinical care (Rao & Sathyanarayana Rao, 2008). Future drug development should move beyond simply managing withdrawal and explore novel targets to address the core neuroadaptations of addiction.
*   **Targeting Stress Systems:** Given the critical role of negative reinforcement and stress in driving relapse, agents that modulate the brain's stress systems are promising candidates (Koob, 2020). This could include antagonists for CRF receptors or agents that target other components of the sensitized stress circuitry in the extended amygdala (Vendruscolo & Koob, 2019).
*   **Glutamatergic Modulators:** As the counterpart to GABAergic inhibition, the glutamatergic system's hyperactivity during withdrawal is a key target (Batinić et al., 2017). Drugs that can safely dampen this excitability, such as novel NMDA receptor antagonists or modulators of metabotropic glutamate receptors, could be effective for both withdrawal management and relapse prevention (Collo & Pich, 2018; Söderpalm, 2002). The rapid antidepressant and potential anti-addictive effects of ketamine suggest this is a particularly fruitful area for investigation (Andrade, 2017; Bundies & Tyagi, 2021).
*   **Neuroinflammatory and Neurotrophic Pathways:** Chronic substance use and stress are associated with neuroinflammation and dysregulation of neurotrophic factors like brain-derived neurotrophic factor (BDNF) (Robertson et al., 2019; Anisman & Merali, 2003). Interventions that target these pathways, perhaps using anti-inflammatory agents or drugs that promote neurogenesis and synaptic plasticity, could potentially reverse some of the drug-induced neural damage and restore healthy brain function (Robertson et al., 2019; Collo & Pich, 2018).

### The Role of Neuromodulation

Non-invasive brain stimulation techniques, such as repetitive transcranial magnetic stimulation (rTMS) and transcranial direct current stimulation (tDCS), offer a novel approach to directly modulate the activity of the dysfunctional brain circuits in addiction (Verma et al., 2018; Chawla et al., 2022). These techniques could be used to enhance activity in the hypoactive prefrontal cortex, thereby improving executive control and impulse inhibition, or to reduce hyperactivity in cue-reactive reward regions (Krsti & Ili, 2014). Deep brain stimulation (DBS), an invasive technique, is also being explored for severe, treatment-refractory addiction, targeting key nodes in the reward circuit like the nucleus accumbens (Groppa et al., 2023; Zarzycki & Domitrz, 2019). While still experimental, these neuromodulation strategies hold the potential to directly correct the circuit-level imbalances that underlie sedative use disorder. Further research is needed to optimize stimulation parameters and identify the patients most likely to benefit (Groppa et al., 2023).

### Integrating Biology with Psychosocial Interventions

Finally, future research must better integrate biological measures with the study of psychosocial interventions. How does CBT for insomnia change resting-state functional connectivity in brain networks related to hyperarousal (Pejović-Nikolić, 2011)? Can we identify biomarkers that predict who will respond best to motivational interviewing versus contingency management? By combining neuroimaging and molecular biology with clinical trials of psychotherapies, we can begin to understand the neural mechanisms through which these interventions work, allowing for their refinement and more targeted application (Franken & Wiers, 2013).

## Conclusion

Sedative, Hypnotic, or Anxiolytic Use Disorder is a chronic and relapsing brain disorder rooted in a complex interplay of neurobiological, genetic, and developmental factors (Clay et al., 2008; Koob, 2020). While the clinical presentation is one of behavioral dyscontrol, the underlying pathology involves profound and persistent changes in the brain's fundamental operating systems. The primary mechanism of action of these substances—the potentiation of the GABAergic system—initiates a cascade of neuroadaptive processes designed to maintain homeostasis in the face of chronic CNS depression (Tseng et al., 2020; Wright, 2020).

This adaptive process, however, becomes maladaptive. The downregulation of GABAergic function leads to tolerance and a state of neuronal hyperexcitability that manifests as a distressing and potentially dangerous withdrawal syndrome upon drug cessation (Pétursson, 1994; Yersin, 1999). Beyond the GABA system, the disorder hijacks the brain's core motivational circuits. The indirect stimulation of the mesolimbic dopamine system provides initial reinforcement, but chronic use leads to a reward deficit, where anhedonia and dysphoria predominate (Koob, 2014; Wise, 1982). Concurrently, the brain's stress systems become sensitized, creating a state of hyperarousal and negative affect that powerfully drives continued drug use through negative reinforcement (Koob, 2020; Vendruscolo & Koob, 2019). This cycle is further entrenched by the impairment of executive functions in the prefrontal cortex, which undermines the individual's capacity for impulse control and rational decision-making (Batinić et al., 2017; Huang & Tsai, 2012).

Vulnerability to this pathological spiral is not uniform. Genetic predispositions influencing neurotransmitter systems and drug metabolism, coupled with developmental factors such as the incomplete maturation of the adolescent brain and the impact of early life stress, can significantly increase an individual's risk (Sussman, 2025; McGorry et al., 2011; van der Kolk, 1998). These biological and developmental vulnerabilities interact with psychosocial factors to shape the trajectory of the disorder.

The biological understanding of sedative use disorder directly informs its clinical management. The necessity of a slow, gradual taper during withdrawal is a direct application of our knowledge of GABA receptor neuroadaptation (Ogbonna & Lembke, 2017). While specific relapse-prevention pharmacotherapies are lacking, addressing the neurobiology of comorbid conditions like depression and anxiety is a rational strategy (Rao & Sathyanarayana Rao, 2008). Furthermore, psychosocial interventions such as cognitive behavioral therapy gain mechanistic support as methods to reduce physiological hyperarousal and strengthen prefrontal cortical control over subcortical drives (Franken & Wiers, 2013).

Moving forward, research must continue to unravel the specific molecular and circuit-level changes induced by this class of drugs. A deeper understanding of genetic risk, epigenetic modifications, and novel neurochemical targets will be essential for the development of more effective and personalized treatments. By viewing Sedative, Hypnotic, or Anxiolytic Use Disorder through a neurobiological lens, we move away from paradigms of moral failing and toward a medical model of a treatable brain disease, offering a more effective and compassionate approach to a significant public health challenge.

## References

1. Aa, K., & Sj, S. (2005). [Palliative sedation, the sympathetic alternative for euthanasia?].. PubMed.
2. Abe, Y., & Germai, A. (2012). Insomnia and Its Correlates: Current Concepts, Epidemiology, Pathophysiology and Future Remarks. InTech eBooks. https://doi.org/10.5772/36102
3. Abou‐Donia, M. B. (2015). Drugs of Abuse. https://doi.org/10.1002/9781118683484.ch26
4. Adam, B. W., Lunow, M., & Seidel, G. (2010). Pseudo-Conn-Syndrom mit hypokaliämischer Lähmung bei Lakritzabusus und Diuretikatherapie. Fortschritte der Neurologie · Psychiatrie. https://doi.org/10.1055/s-0029-1245912
5. Adam, Z., Klimeš, J., Pour, L., Král, Z., Onderková, A., Čermák, A., & Vorlíček, J. (2019). Maligní onemocnění, psychika a stres: příběhy pacientů s komentářem psychologa.
6. Adiga, M., Shruti, & Rajashekhar, C. V. (2021). A ROLE OF AYURVEDA IN THE MANAGEMENT OF APASMARA (EPILEPSY): A CASE STUDY. International Journal of Research in Ayurveda and Pharmacy. https://doi.org/10.7897/2277-4343.1204100
7. Agarwal, V., Sitholey, P., & Srivastava, C. (2019). Clinical practice guidelines for the management of dissociative disorders in children and adolescents. Indian Journal of Psychiatry. https://doi.org/10.4103/psychiatry.indianjpsychiatry_493_18
8. Albano, A. M., & Silverman, W. K. (2024). Major Depressive Disorder. Oxford University Press eBooks. https://doi.org/10.1093/med-psych/9780199348367.003.0014
9. Albano, A. M., & Silverman, W. K. (2024). Major Depressive Disorder. Oxford University Press eBooks. https://doi.org/10.1093/med-psych/9780199348381.003.0014
10. Albuquerque, A. C. D., Silva, J. R. D., & Silva, J. (2015). The “roundabout Man” Trapped in the “roundabout City” – a Case Report of a Severe Obsessive Compulsive Disorder. European Psychiatry. https://doi.org/10.1016/s0924-9338(15)32056-3
11. Ali, H., & Stevens, S. (2020). 1219 A CASE OF A NIGHT TIME AFFAIR. SLEEP. https://doi.org/10.1093/sleep/zsaa056.1213
12. Ali, M., Malathesh, B. C., Chatterjee, S. S., Das, S., & Prasad, S. (2022). Mania/Hypomania induced by quetiapine: A case report and review of literature. Psychiatry Research Case Reports. https://doi.org/10.1016/j.psycr.2022.100093
13. Ambrosini, A., & Schoenen, J. (2010). Commentary on Fontaine et al.: Safety and efficacy of deep brain stimulation in refractory cluster headache: a randomized placebo-controlled double-blind trial followed by a 1-year open extension. The Journal of Headache and Pain. https://doi.org/10.1007/s10194-009-0184-5
14. Ameringen, M. V., Allgulander, C., Bandelow, B., Greist, J. H., Hollander, E., Montgomery, S., Nutt, D., Okasha, A., Pollack, M. H., Stein, D. J., & Swinson, R. P. (2003). WCA Recommendations for the Long-Term Treatment of Social Phobia. CNS Spectrums. https://doi.org/10.1017/s1092852900006933
15. Amorim, M. J., Maurício, J., & Brandão, D. (2019). WHEN THE DISEASE ARISES FROM THE TREATMENT: CORTICOSTEROID-INDUCED PSYCHOSIS A CASE REPORT AND BRIEF LITERATURE REVIEW. https://doi.org/10.26226/morressier.5d1a037b57558b317a140b63
16. Amron, S. B., Kandasami, G., Lee, C., Guo, S. L., & Tan, H. (2025). Making sense of ICD-11 diagnostic criteria of compulsive sexual behavioural disorder. Annals of the Academy of Medicine Singapore. https://doi.org/10.47102/annals-acadmedsg.2024266
17. Ancoli‐Israel, S. (2005). Sleep and aging: prevalence of disturbed sleep and treatment considerations in older adults.. PubMed.
18. Anderson, M. (2010). Benzodiazepines for prolonged seizures. Archives of Disease in Childhood Education & Practice. https://doi.org/10.1136/adc.2009.176321
19. Andersson, E., Hovland, A., Taube, J., Kjellman, B., Hedlund, L., & Martinsen, E. W. (2022). [Physical activity has an acute effect on depression and anxiety syndromes].. PubMed.
20. Andrade, C. (2012). Drugs That Escape Hepatic Metabolism. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.12f07726
21. Andrade, C. (2017). Ketamine for Depression, 1: Clinical Summary of Issues Related to Efficacy, Adverse Effects, and Mechanism of Action. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.17f11567
22. Andrade, C. (2022). Psychotropic Drugs With Long Half-Lives. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.22f14593
23. Anggela, S., & Hanum, N. A. (2020). HUBUNGAN KEBIASAAN BURUK ORAL (BAD ORAL HABITS) DENGAN KARIES PADA ANAK USIA PRA-SEKOLAH.
24. Anis, A., Noor, S., & Shakeel, A. (2025). Attention deficit hyperactivity disorder: a misdiagnosed disorder. International Journal of Scientific Reports. https://doi.org/10.18203/issn.2454-2156.intjscirep20250752
25. Anisman, H., & Merali, Z. (2003). Cytokines, stress and depressive illness: brain‐immune interactions. Annals of Medicine. https://doi.org/10.1080/07853890310004075
26. Anisman, H., Merali, Z., Poulter, M. O., & Hayley, S. (2005). Cytokines as a Precipitant of Depressive Illness: Animal and Human Studies. Current Pharmaceutical Design. https://doi.org/10.2174/1381612053381701
27. Antonio, E., & Alfredo, E. (2012). Cocaine Addiction: Changes in Excitatory and Inhibitory Neurotransmission. InTech eBooks. https://doi.org/10.5772/34410
28. Arens, C., & Schwemmle, C. (2018). [Feeding, eating, and swallowing disorders in infants and children : An overview]..
29. Aretouli, E., Malik, M., Widmann, C., Parker, A. M., Oh, E. S., & Vannorsdall, T. D. (2025). Cognitive and mental health outcomes in long covid. BMJ. https://doi.org/10.1136/bmj-2024-081349
30. Armstrong, E. (1995). Anxiety and related problems. https://doi.org/10.1007/978-1-349-13362-8_5
31. Arpacı, A. H., Koç, A., Gürkan, Ö. E., Tosun, C., & Işık, B. (2017). Emergence Agitation or Excited Delirium. Gazi Medical Journal.
32. Arredondo-Aldana, K., Mera-Posligua, M. J., & Alencastro, J. A. P. (2021). Trastorno Depresivo Persistente y Trastornos de Ansiedad Generalizada Proveniente de un Estrés Post Traumático Crónico: Presentación de un Caso Clínico. Revista Científica Arbitrada en Investigaciones de la Salud GESTAR. https://doi.org/10.46296/gt.v4i8edesp.0027
33. Arteaga, T. L., Amo, C., González, C. S., & Sánchez, D. H. (2013). Nonconvulsive status epilepticus and psychotic symptoms: case report.. PubMed. https://doi.org/10.1708/1292.14295
34. Ashraf, M., Sheikher, C., Farooq, A., & Ahmed, J. (2012). Shuddering attacks: Should an EEG be ordered. Biomedical Reports.
35. Autor, S. (2002). CÁPSULAS PARA LA VIDA.- ANSIEDAD. Gaceta UNAM (2000-2009).
36. Avidan, A. Y., & Grigg‐Damberger, M. (2019). LA Night Moves. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190671099.003.0004
37. Avidan, M. S., & Evers, A. S. (2011). Review of Clinical Evidence for Persistent Cognitive Decline or Incident Dementia Attributable to Surgery or General Anesthesia. Journal of Alzheimer s Disease. https://doi.org/10.3233/jad-2011-101680
38. Ayala, L., Gómez‐Revuelta, M., Requena, C. M., Acilu, E. S. D. A. G. D., Olivares, O. P., Ruíz, M. J., Morales, N. N., Martin, M., Zufiaurre, M. L., Hernández, B., Itoiz, A. A., Peña, M., & González‐Pinto, A. (2017). Clozapine: Since the very beginning?. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2017.01.1402
39. Aytaş, Ö., & Yalvaç, H. D. (2015). Modafinil-Induced Psychosis: A Case Report. Nöro Psikiyatri Arşivi. https://doi.org/10.5152/npa.2015.7160
40. Ayşe, H., Hakkı, ©., Arpacı, A. H., Koç, A., Gürkan, Ö. E., Tosun, C., & Işık, B. (2017). Emergence Agitation or Excited Delirium?. Gazi Medical Journal. https://doi.org/10.12996/gmj.2017.45
41. Ba, V. D. K. (1998). [Psychology and psychobiology of childhood trauma].. PubMed.
42. Baandrup, L., Jennum, P., Lublin, H., & Glenthøj, B. (2012). Treatment options for residual insomnia in schizophrenia. Acta Psychiatrica Scandinavica. https://doi.org/10.1111/acps.12016
43. Backer, W. D. (2006). Obstructive Sleep Apnea-Hypopnea Syndrome. KARGER eBooks. https://doi.org/10.1159/000093150
44. Bajabir, D., Almurayyi, E., Alrashidi, A., Alshahrani, I., Almutairy, A., Alqahtan, S., Alqurashi, G., Alattas, M. H., Nawb, Y., Alshammari, B., & Alahmari, S. (2022). Pharmacological Strategies and Challenges in Treatment-Resistant Bipolar Depression. Journal of Healthcare Sciences. https://doi.org/10.52533/johs.2022.21211
45. Baldwin, D. S. (2006). The importance of long-term tolerability in achieving recovery. International Journal of Psychiatry in Clinical Practice. https://doi.org/10.1080/13651500600552552
46. Balhara, Y. P. S., Mohan, I., Sagar, R., & Chawla, J. (2006). Chronic mania: An unexpectidly long episode?. Indian Journal of Medical Sciences. https://doi.org/10.4103/0019-5359.25681
47. Ballantyne, J. C., & Shin, N. S. (2008). Efficacy of Opioids for Chronic Pain. Clinical Journal of Pain. https://doi.org/10.1097/ajp.0b013e31816b2f26
48. Banerjee, S., Bhandari, R. P., & Rosenberg, D. R. (2005). Use of Low-Dose Selective Serotonin Reuptake Inhibitors for Severe, Refractory Choking Phobia in Childhood. Journal of Developmental & Behavioral Pediatrics. https://doi.org/10.1097/00004703-200504000-00008
49. Barbosa, M. V. A., Perosso, B. T., Tufik, S., Andersen, M. L., Morelhão, P. K., & Gobbi, C. (2022). Self-Efficacy: What Is Your Role in the Sleep and Pain of Patients with Chronic Shoulder Pain?. Pain Medicine. https://doi.org/10.1093/pm/pnac123
50. Barch, D. M., Pagliaccio, D., Luking, K. R., Moran, E. K., & Culbreth, A. J. (2019). Pathways to Motivational Impairments in Psychopathology: Common Versus Unique Elements Across Domains. Nebraska Symposium on Motivation/The Nebraska symposium on motivation. https://doi.org/10.1007/978-3-030-27473-3_5
51. Barnes, T. R. E. (2018). Pharmacological management of treatment-resistant schizophrenia: alternatives to clozapine. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198828761.003.0009
52. Barnhill, J. W., Okuda, M., Simpson, H. B., Stein, D. J., Simpson, H. B., Phillips, K. A., Phillips, K. A., Mataix‐Cols, D., Cruz, L. F. D. L., & Stein, D. J. (2023). Obsessive-Compulsive and Related Disorders. American Psychiatric Association Publishing eBooks. https://doi.org/10.1176/appi.books.9781615375295.jb06
53. Barron, A., Salvador, M., García-Diego, A. C., & López, M. M. (2025). Management of insomnia evaluated by the Psychiatry Interconsultation in a patient with a comorbid medical condition. European Psychiatry. https://doi.org/10.1192/j.eurpsy.2025.2328
54. Bartels, K., & Schacht, J. P. (2021). Cocaine-Positive Patients Undergoing Elective Surgery: From Avoiding Case Cancellations to Treating Substance Use Disorders. Anesthesia & Analgesia. https://doi.org/10.1213/ane.0000000000004969
55. Bartova, L., Dold, M., Volz, H. P., Seifritz, E., Möller, H., & Kasper, S. (2025). ANTIDEPRESSANT EFFECTS OF SILEXAN IN PATIENTS WITH PRIMARY ANXIETY SYNDROMES. The International Journal of Neuropsychopharmacology. https://doi.org/10.1093/ijnp/pyae059.065
56. Basura, G. J., Adams, M. E., Monfared, A., Schwartz, S., Antonelli, P. J., Burkard, R., Bush, M. L., Bykowski, J., Colandrea, M., Derebery, J., Kelly, E. A., Kerber, K. A., Koopman, C. F., Kuch, A. A., Marcolini, E. G., McKinnon, B. J., Ruckenstein, M. J., Valenzuela, C. V., Vosooney, A., ... Buchanan, E. (2020). Clinical Practice Guideline: Ménière’s Disease Executive Summary. Otolaryngology. https://doi.org/10.1177/0194599820909439
57. Basura, G. J., Adams, M. E., Monfared, A., Schwartz, S., Antonelli, P. J., Burkard, R., Bush, M. L., Bykowski, J., Colandrea, M., Derebery, J., Kelly, E. A., Kerber, K. A., Koopman, C. F., Kuch, A. A., Marcolini, E. G., McKinnon, B. J., Ruckenstein, M. J., Valenzuela, C. V., Vosooney, A., ... Buchanan, E. M. (2020). Clinical Practice Guideline: Ménière’s Disease. Otolaryngology. https://doi.org/10.1177/0194599820909438
58. Batinić, B., Duišin, D., & Vukosavljevic-Gvozden, T. (2017). Neurobiological bases for impulsive and compulsive behaviour: Implications for pharmacological and psychological interventions. Engrami. https://doi.org/10.5937/engrami1701017b
59. Baumann, P., & Martin-Du, P. R. (2008). Sexual dysfunctions induced by antidepressants and antipsychotics.
60. Baumeister, R. F., & Heatherton, T. F. (1996). Self-Regulation Failure: An Overview. Psychological Inquiry. https://doi.org/10.1207/s15327965pli0701_1
61. Baumeister, R. F., Vonasch, A., & Sjåstad, H. (2020). The Long Reach of Self-Control. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780197500941.003.0002
62. Bausewein, C., & Schildmann, E. (2022). Symptomkontrolle am Lebensende. Therapeutische Umschau. https://doi.org/10.1024/0040-5930/a001327
63. Baxter, P. (2015). States of consciousness: new insights and further questions. Developmental Medicine & Child Neurology. https://doi.org/10.1111/dmcn.12666
64. Beek, N. V. (2003). Vulnerability factors in panic disorder patients and their first-degree relatives : inquiries into carbon dioxide vulnerability, anxiety sensitivity, and respiratory pathology. https://doi.org/10.26481/dis.20031017nb
65. Beghi, M., Cornaggia, C., Frigeni, B., & Beghi, E. (2006). Learning Disorders in Epilepsy. Epilepsia. https://doi.org/10.1111/j.1528-1167.2006.00681.x
66. Behrman, S., & Ebmeier, K. P. (2014). Can exercise prevent cognitive decline?. PubMed.
67. Berastegui, C., Monfort, E., & Boudin, B. (2017). Vocally disruptive behaviors management in older people with dementia. Gériatrie et Psychologie Neuropsychiatrie du Viellissement. https://doi.org/10.1684/pnv.2017.0657
68. Bereda, G. (2023). Seizures Are the Main Sign of Epilepsy: Stages of Seizures. Pathology and Laboratory Medicine. https://doi.org/10.11648/j.plm.20230701.11
69. Bertodo, T. D. S., Gross, M. S., & Maldaner, E. B. (2018). TRANSTORNOS BIPOLAR E DEPRESSIVO: UMA REVISÃO DOS ASPECTOS CONCEITUAIS.
70. Birschel, P., Ellul, J., & Barer, D. (2003). Progressing Stroke: Towards an Internationally Agreed Definition. Cerebrovascular Diseases. https://doi.org/10.1159/000076161
71. Bischoff, P., & Rundshagen, I. (2011). Awareness Under General Anesthesia. Deutsches Ärzteblatt international. https://doi.org/10.3238/arztebl.2011.0001
72. Bismuth, C., Bellec, L., Dally, S., & Lagier, G. (1980). [Benzodiazepine physical dependence. 6 cases (author's transl)].. PubMed.
73. Bittencourt, L., Silva, R. S., Santos, R. F., Pires, M. L. N., & Mello, M. T. D. (2005). Sonolência excessiva. Brazilian Journal of Psychiatry. https://doi.org/10.1590/s1516-44462005000500004
74. Blumenthal, J. A., & Lett, H. S. (2005). Depression and Cardiac Risk. Journal of Cardiopulmonary Rehabilitation. https://doi.org/10.1097/00008483-200503000-00005
75. Bogan, R., Thorpy, M. J., Berkowitz, S., & Gudeman, J. (2025). How once-nightly sodium oxybate is processed in the body in healthy volunteers: a plain language summary. Journal of Comparative Effectiveness Research. https://doi.org/10.57264/cer-2024-0243
76. Bolton, E., Holohan, D. R., King, L. A., & King, D. W. (2004). Acute and Post-Traumatic Stress Disorder. Routledge eBooks. https://doi.org/10.4324/9780203336960-13
77. Bourdeanu, L., Hein, M. J., & Liu, E. A. (2015). Insomnia. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190244330.003.0011
78. Bourin, M., & Thibaut, F. (2013). How Assess Drugs in the Treatment of Acute Bipolar Mania?. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2013.00004
79. Brashear, A., Sweadner, K. J., Cook, J., Swoboda, K. J., & Ozelius, L. J. (2014). ATP1A3-Related Neurologic Disorders. University of Washington, Seattle eBooks.
80. Breggin, P. R. (1999). Psychostimulants in the treatment of children diagnosed with ADHD: Risks and mechanism of action. International Journal of Risk & Safety in Medicine. https://doi.org/10.3233/jrs-1999-177
81. Breuer, L., Kasper, B. S., Schwarze, B., Gschossmann, J. M., Kornhuber, J., & Müller, H. (2015). “Herbal seizures” – atypical symptoms after ibogaine intoxication: a case report. Journal of Medical Case Reports. https://doi.org/10.1186/s13256-015-0731-4
82. Brignole, M. (2006). Neurally mediated syncope. CRC Press eBooks. https://doi.org/10.1201/b13301-22
83. Broniarczyk-Czarniak, M., Sowińska, K., Białas, J., & Talarowska, M. (2019). Ciężka depresja z nasilonymi zaburzeniami funkcji poznawczych czy otępienie.
84. Bruch, S. (2013). Cultural concerns and issues in emergency psychiatry. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9781139088077.041
85. Bruin, E. I. D., Meppelink, R., & Bögels, S. M. (2020). Mindfulness in attention deficit hyperactivity disorder. Routledge eBooks. https://doi.org/10.4324/9781315563862-7
86. Brückner, K. (2020). Cognitive and Psychological Side Effects of Antiepileptic Drugs. IntechOpen eBooks. https://doi.org/10.5772/intechopen.94308
87. Brüne, M. (2015). Obsessive-compulsive and related disorders. Oxford University Press eBooks. https://doi.org/10.1093/med:psych/9780198717942.003.0012
88. Brădeanu, A. V., Pascu, L. S., Ungurianu, S., Tutunaru, D., Rebegea, L., Terpan, M., & Ciubară, A. (2019). The Effect of Behaviour in Patients Who Are Hospitalized and Suffer from Alcohol Withdrawal. BRAIN BROAD RESEARCH IN ARTIFICIAL INTELLIGENCE AND NEUROSCIENCE. https://doi.org/10.70594/brain/v10.s2/5
89. BSc, P. L. G. R., & BSc, D. B. R. (2008). Glossary of Technical Terms. https://doi.org/10.1002/9781444302264.gloss
90. Buckley, P. (1999). The role of typical and atypical antipsychotic medications in the management of agitation and aggression.. PubMed.
91. Budson, A. E., & O’Connor, M. K. (2021). How to manage emotional problems. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780190098124.003.0008
92. Budson, A. E., & O’Connor, M. K. (2021). Which medications can improve thinking, memory, behavior, or function?. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780190098124.003.0013
93. Bundalo-Vrbanac, D., Buljan, D., Peitl, V., & Gelo, J. (2012). Integrating Psychotherapy and Pharmacotherapy in Treatment of Substance Dependence. Alcoholism and psychiatry research Journal on psychiatric research and addictions.
94. Bundies, G. L., & Tyagi, H. (2021). #3095 Rapid anti-obsessive treatments of obsessive-compulsive disorder: reviewing effects of ketamine in OCD. Journal of Neurology Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp-2021-bnpa.24
95. Burk, A., Merchant, A., Rahman, H., Patel, A., Deshmukh, I., Merchant, R., Yam, A. A., Yu, A., Cai, C., Hassam, A., Le, D., & Lambroussis, C. G. (2025). Serotonin Syndrome Without Overdose: Polypharmacy-Induced Toxicity in a Medically Stable Young Adult. Cureus. https://doi.org/10.7759/cureus.86587
96. Burn, D. J. (2013). Approach to History Taking and Examination of the Movement Disorder Patient. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199609536.003.0002
97. Burton, K., & Kendall, N. (2014). ABC of Occupational and Environmental Medicine, 3rd EditionMusculoskeletal Disorders.
98. Bénony, H., Bénony-Viodé, C., & Dumas, J. (2012). Le trouble hyperkinétique ou déficit de l'attention/hyperactivité. Le point sur... Psychologie.
99. Bénony, H., Bénony-Viodé, C., & Dumas, J. (2012). Les troubles de l'humeur. Le point sur... Psychologie.
100. Bürk, K., Strelczyk, A., & Oertel, W. H. (2012). Intermittent Tunnel Vision in a Patient With Multiple Drug Abuse History. Movement Disorders. https://doi.org/10.1891/9781617050589.0090
101. Cabrejo-Mendoza, H. J., & Albornoz-Muñoz, D. P. (2023). Trastorno de Acumulación: A propósito de un caso. Revista de Neuro-Psiquiatría. https://doi.org/10.20453/rnp.v86i1.4469
102. Cadoret, R. J., & Winokur, G. (1972). Genetic Principles in the Classification of Affective Illnesses. International Journal of Mental Health. https://doi.org/10.1080/00207411.1972.11448572
103. Camkurt, M. A., Yılmaz, M., & Güneş, S. (2015). Spontaneous ejaculation induced by duloxetine. Anatolian Journal of Psychiatry. https://doi.org/10.5455/apd.189811
104. Capaldi, D. M., & Kim, H. K. (2014). Comorbidity of Depression and Conduct Disorder. Oxford University Press eBooks. https://doi.org/10.1093/oxfordhb/9780199797004.013.015
105. Cardeña, E. (2018). Derangement of the senses or alternate epistemological pathways? Altered consciousness and enhanced functioning.. Psychology of Consciousness Theory Research and Practice. https://doi.org/10.1037/cns0000175
106. Carod-Artal, F. J., Irimia, P., & Ezpeleta, D. (2012). Migraña crónica: definición, epidemiología, factores de riesgo y tratamiento. Revista de Neurología. https://doi.org/10.33588/rn.5410.2012170
107. Casey, D. E., Korsgaard, S., Gerlach, J., Jørgensen, A., & Simmelsgaard, H. (1981). Effect of Des-Tyrosine-γ-Endorphin in Tardive Dyskinesia. Archives of General Psychiatry. https://doi.org/10.1001/archpsyc.1981.01780270044005
108. CASEY, P., & Bailey, S. (2011). Adjustment disorders: the state of the art. World Psychiatry. https://doi.org/10.1002/j.2051-5545.2011.tb00003.x
109. Castellanos, G., Escobar, A. P., & González, B. G. (2006). Estrés y conducta adictiva. DELETED.
110. Catheline, N. (2005). [Academic problems and school failure in adolescence].. PubMed.
111. Cha, Y., Baloh, R. W., Cho, C., Magnusson, M., Song, J., Strupp, M., Wuyts, F. L., & Staab, J. P. (2020). Mal de débarquement syndrome diagnostic criteria: Consensus document of the Classification Committee of the Bárány Society. Journal of Vestibular Research. https://doi.org/10.3233/ves-200714
112. Challacombe, F., & Wroe, A. L. (2013). A hidden problem: consequences of the misdiagnosis of perinatal obsessive–compulsive disorder. British Journal of General Practice. https://doi.org/10.3399/bjgp13x667376
113. Chang, A. N., Kiyokawa, M., & Grysman, N. (2025). Cocaine Induced Postictal Psychosis: a Rare Cause of Antipsychotic Resistant Psychosis. Hawai‘i Journal of Health &amp Social Welfare. https://doi.org/10.62547/nmiq4624
114. Chaouloff, F., Dubreucq, S., Matias, I., & Marsicano, G. (2013). Physical activity feel-good effect:The role of endocannabinoids. Routledge eBooks. https://doi.org/10.4324/9780203132678-12
115. Charlton, S. R. (2020). Psychology and Black History Month in the United States. Eye on Psi Chi Magazine. https://doi.org/10.24839/2164-9812.eye24.4.18
116. Chatterjee, S., Rudra, A., Kirtania, J., Sengupta, S., Moitra, G., Sirohia, S., Wankhade, R., & Banerjee, S. (2006). Postoperative delirium. Indian Journal of Critical Care Medicine. https://doi.org/10.4103/0972-5229.29842
117. Chatterton, C., & Jones, G. (2013). Interpretative aspects of toxicological results. https://doi.org/10.4155/ebo.13.54
118. Chaudhry, S. (2020). Depression and its Dilemma. IP Journal of Surgery and Allied Sciences. https://doi.org/10.18231/j.jsas.2020.013
119. Chauhan, R., Bhunal, S., Gupta, D., Kumar, R., & Sharma, T. (2020). TO STUDY CLINICAL PROFILE OF ACUTE CONFUSIONAL STATE IN A TERTIARY CARE HOSPITAL IN A HILLY AREA.. International Journal of Scientific Research. https://doi.org/10.36106/ijsr/0915904
120. Chawla, K., Singh, S., Singh, A., & Kar, S. K. (2022). Augmentation with Transcranial Direct Current Stimulation in Difficult to Treat Obsessive-Compulsive Disorder. Annals of Indian Psychiatry. https://doi.org/10.4103/aip.aip_124_22
121. Chen, Z., & Gong, Q. (2021). Resting-State Functional Connectivity in Unipolar Depression. Cambridge University Press eBooks. https://doi.org/10.1017/9781108623018.007
122. Chow, W., Khullar, A., Lalla, F., Lessard, S., Lowe, A., & McIntosh, D. (2025). Practical Recommendations for Hypnotic Switching in Insomnia Management: A Canadian Expert Clinical Framework. Canadian Primary Care Today. https://doi.org/10.58931/cpct.2025.3s0148
123. Chu, M. K. (2006). Pharmacologic Treatments of Insomnia. Journal of Korean Sleep Research Society. https://doi.org/10.13078/jksrs.06008
124. Chumpitazi, C. E. (2018). Minor Adverse Events. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190659110.003.0022
125. Chumpitazi, C. E. (2018). Moderate Adverse Events. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190659110.003.0023
126. Cienfuegos, J. J., Arriaga, M. Á. A., García, J. J., & Fernández, A. C. S. (2021). Propuesta de establecimiento de hábitos y rutinas que contemplen ejercicio y manejo del estrés para evitar el desgaste laboral durante el home office. Ciencia Latina Revista Científica Multidisciplinar. https://doi.org/10.37811/cl_rcm.v5i3.583
127. Clark, J. D., Rager, D. R., & Calpin, J. P. (1997). Animal well-being. II. Stress and distress.. PubMed.
128. Clay, S., Allen, J. V., & Parran, T. (2008). A Review of Addiction. Postgraduate Medicine. https://doi.org/10.3810/pgm.2008.07.1802
129. Cocchi, R., & Tornati, A. (1977). [Psychological dependence? A possible different formulation of the problem for a therapeutic rearrangement in chronic drug addictions].. PubMed.
130. Cocchi, R., & Tornati, A. (1977). Psychic dependence? A different formulation of the problem with a view to the reorientation of therapy for chronic drug addiction. Acta Psychiatrica Scandinavica. https://doi.org/10.1111/j.1600-0447.1977.tb06675.x
131. Coccolini, F., Improta, M., Picetti, E., Vergano, L. B., Catena, F., Angelis, N. D., Bertolucci, A., Kirkpatrick, A. W., Sartelli, M., Fugazzola, P., Tartaglia, D., & Chiarugi, M. (2020). Timing of surgical intervention for compartment syndrome in different body region: systematic review of the literature. World Journal of Emergency Surgery. https://doi.org/10.1186/s13017-020-00339-8
132. Coimbra, I. B. (2017). Avaliação dos fatores psicossociais, estratégias de "coping" e síndrome de "Burnout" na residência médica. https://doi.org/10.47749/t/unicamp.2017.988423
133. Collo, G., & Pich, E. M. (2018). Ketamine enhances structural plasticity in human dopaminergic neurons: possible relevance for treatment-resistant depression. Neural Regeneration Research. https://doi.org/10.4103/1673-5374.230288
134. Conway, K. P., Montoya, I. D., & Compton, W. M. (2007). Lifetime Psychiatric Comorbidity of Illicit Drug Use Disorders. The Psychiatric times.
135. Cooney, G. (2013). Exercise for depression. Journal of Evidence-Based Medicine. https://doi.org/10.1111/jebm.12076
136. Coronado, L. M. Q., Florez, D. A. C., & Tarazona, M. C. L. (2017). Prevalencia depresión en estudiantes universitarios Bucaramanga 2017.
137. Corrêa, C. R. G. L. (2013). Attention – Deficit Hyperactivity Disorder (ADHD) in Psychiatry and Psychoanalysis. InTech eBooks. https://doi.org/10.5772/52880
138. Cuesta-Vargas, Á., Gonzlez-Snchez, M., Manzanares, M. T. L., & Galn-Mercant, A. (2012). Physiotherapy Treatment on Chronic Non Specific Low Back Pain. InTech eBooks. https://doi.org/10.5772/34756
139. Cuevas, M. J. S. (2005). EL TRASTORNO POR DÉFICIT DE ATENCIÓN CON HIPERACTIVIDAD (314.01) Y SU INCIDENCIA EN EL MEDIO ESCOLAR, FAMILIAR Y SOCIAL EN EL CAMPO DE GIBRALTAR. Almoraima:  revista de estudios campogibraltareños.
140. Culberson, J., & Ziska, M. (2008). Prescription drug misuse/abuse in the elderly.. PubMed.
141. Cunnington, D., Junge, M., & Fernando, A. (2013). Insomnia: prevalence, consequences and effective treatment. The Medical Journal of Australia. https://doi.org/10.5694/mja13.10718
142. Dalamagka, M. I. (2024). Emergence Delirium in children. International Journal of Science and Research Archive. https://doi.org/10.30574/ijsra.2024.12.2.1408
143. Daley, D. C., & Douaihy, A. (2006). The Recovery Process for Addiction and Mood Disorders. https://doi.org/10.1093/oso/9780195311297.003.0004
144. Daley, D. C., & Douaihy, A. (2019). Medications for Substance Use Disorders. Oxford University Press eBooks. https://doi.org/10.1093/med-psych/9780190926717.003.0006
145. Daley, D. C., & Douaihy, A. (2019). Substance-Related Disorders. Oxford University Press eBooks. https://doi.org/10.1093/med-psych/9780190926632.003.0002
146. Dam, A. V., Eling, P., Keijsers, G. P. J., & Becker, E. S. (2013). Do Employees with Burnout Prefer Low-Effort Performance Strategies?. IIE Transactions on Occupational Ergonomics and Human Factors. https://doi.org/10.1080/21577323.2013.828666
147. Darriba, H. B. (2023). A complex polymorphous psychosis or a cycloid psychosis with a different onset?. European Psychiatry. https://doi.org/10.1192/j.eurpsy.2023.2246
148. Das, C., & Joseph, S. (2005). Falls in elderly.. PubMed.
149. Deantri, F., & Sawitri, A. A. S. (2020). PROPORSI STRES DAN GEJALA PSIKOSOMATIK PADA SISWA KELAS XII SEKOLAH MENENGAH ATAS DI KOTA DENPASAR. JURNAL BIOS LOGOS. https://doi.org/10.35799/jbl.10.1.2020.27465
150. Delanerolle, G., Shetty, S., Raymont, V., Hapangama, D. K., Haque, N., Shi, J. Q., Ayis, S., Shetty, A., & Phiri, P. (2021). None. LOJ Medical Sciences. https://doi.org/10.32474/lojms.5.5
151. Delgado, D. A. O., Rojas, M. C. O., & Olea, J. M. S. (2024). Episodio depresivo mayor de características catatónicas: Reporte de caso. Revista Científica de Salud y Desarrollo Humano. https://doi.org/10.61368/r.s.d.h.v5i1.75
152. Deng, S., Sheng, H.-Z., Zhou, Y., & Zhang, J. (2019). Whether we could forget pain or not after the scar healed? A discussion about changing the acute pain into chronic pain. Pain Clin J. https://doi.org/10.3760/cma.j.issn.1672-9633.2019.05.003
153. Derman, E., Whitesman, S., Dreyer, M., Patel, D., Nossel, C., & Schwellnus, M. (2010). Healthy lifestyle interventions in general practice: Part 12: Lifestyle and depression. South African Family Practice. https://doi.org/10.1080/20786204.2010.10873989
154. Desai, S. V., Law, T. J., & Needham, D. M. (2010). Long-term complications of critical care. Critical Care Medicine. https://doi.org/10.1097/ccm.0b013e3181fd66e5
155. Devlin, J. W., Mallow-Corbett, S., & Riker, R. R. (2010). Adverse drug events associated with the use of analgesics, sedatives, and antipsychotics in the intensive care unit. Critical Care Medicine. https://doi.org/10.1097/ccm.0b013e3181de125a
156. Deyo, R. A., Korff, M. V., & Duhrkoop, D. (2015). Opioids for low back pain. BMJ. https://doi.org/10.1136/bmj.g6380
157. Dhillon, R. S. (2013). The Potential for Abuse: Addiction. Berkeley Scientific Journal. https://doi.org/10.5070/bs3181020649
158. Dhingra, L., Ahmed, E., Shin, J. G., Scharaga, E., & Magun, M. (2015). Cognitive Effects and Sedation. Pain Medicine. https://doi.org/10.1111/pme.12912
159. Dias, R. D. S. (2010). Estudo comparativo do fenótipo clínico de mulheres com transtorno afetivo bipolar em fase reprodutiva da vida com e sem piora pré-menstrual do humor. https://doi.org/10.11606/t.5.2010.tde-28052010-101220
160. Diener, H., Holle, D., Dresler, T., & Gaul, C. (2018). Chronic Headache Due to Overuse of Analgesics and Anti-Migraine Agents. Deutsches Ärzteblatt international. https://doi.org/10.3238/arztebl.2018.0365
161. Dilsaver, S. C., Halle, M. H., & Medico, V. J. D. (1991). Symptoms of major depression: acute effect of withdrawing antidepressants. Acta Psychiatrica Scandinavica. https://doi.org/10.1111/j.1600-0447.1991.tb05531.x
162. Djamshidian, A., Pagnier, G., Frank, M. J., & Friedman, J. H. (2022). Impulse Control Disorders and the Dopamine Dysregulation Syndrome. Cambridge University Press eBooks. https://doi.org/10.1017/9781009039291.021
163. Dobrescu, I., Rad, F., Anghel, G. C., Stancu, M., & Buică, A. (2017). P288 Somatic complaints in anxiety disorders. https://doi.org/10.1136/archdischild-2017-313273.376
164. Dodd, M. L. (2007). BASIC PRINCIPLES OF PSYCHIATRY. CRC Press eBooks. https://doi.org/10.1201/b14430-11
165. Dr.V, S. (2020). INNOVATIVE RESEARCH ABOUT SCHOOL TEACHERS STRESS AND SUSTAINABLE STRATEGIES TO ELIMINATE SCHOOL TEACHERS STRESS. International Journal of Psychosocial Rehabilitation. https://doi.org/10.37200/ijpr/v24i4/pr201100
166. Drago, F., & Caraci, F. (2020). Faculty Opinions recommendation of Treatment of behavioral and psychological symptoms of dementias with psychopharmaceuticals: a review.. Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature. https://doi.org/10.3410/f.733303213.793576054
167. DRISCOLL, P. L. (2009). MAINTENANCE MEDICATION FOR CHRONIC SCHIZOPHRENICS: RISK/BENEFIT ASSESSMENT. Perspectives In Psychiatric Care. https://doi.org/10.1111/j.1744-6163.1985.tb00264.x
168. Drogin, E. Y., Dattilio, F. M., Sadoff, R. L., & Gutheil, T. G. (2011). Appendix A: Scientific Glossary. https://doi.org/10.1002/9781118093399.app1
169. Dudek, D., & Sobański, J. A. (2012). Mental disorders in somatic diseases: psychopathology and treatment. Polskie Archiwum Medycyny Wewnętrznej. https://doi.org/10.20452/pamw.1539
170. Duncan, J. S. (1988). Neuropsychiatric aspects of sedative drug withdrawal. Human Psychopharmacology Clinical and Experimental. https://doi.org/10.1002/hup.470030304
171. Duncan, J. S. (2005). Medico-legal aspects of epilepsy. Meritus Communications eBooks.
172. Dunn, D. W., & Kronenberger, W. G. (2015). Attention, Executive Function, and Attention Deficit Hyperactivity Disorder. Neuropsychiatric symptoms of neurological disease. https://doi.org/10.1007/978-3-319-22159-5_13
173. Dégeilh, F., Viard, A., Dayan, J., Guenolé, F., Egler, P., Baleyte, J., Eustache, F., & Guillery‐Girard, B. (2013). Memory impairment in post-traumatic stress disorder: Behavioral and neuroimaging findings. Revue de neuropsychologie.
174. d’Andrea, G., Marco, O. D., Semeraro, F. M., Carullo, R., Sensi, S. L., Pettorruso, M., & Martinotti, G. (2023). Intranasal esketamine as tool for rapid cycling bipolar disorder: A case report of successful mood stabilization. Psychiatry Research Case Reports. https://doi.org/10.1016/j.psycr.2023.100188
175. D’cruz, M., Andrade, C., & Rao, T. S. (2020). The Expression of Intimacy and Sexuality in Persons With Dementia. Journal of Psychosexual Health. https://doi.org/10.1177/2631831820972859
176. Easterling, S., Master, V. A., & Carney, K. J. (2014). Evaluation and management of patients with nocturia. JAAPA. https://doi.org/10.1097/01.jaa.0000442703.33717.85
177. Ebrahimi, H. A., & Ebrahimi, F. (2012). The effect of lamotrigine on epilepsy.. PubMed.
178. Edge, R., & Argáez, C. (2021). Droperidol for Agitation in Acute Care [Internet].
179. Edinger, J. D., & Carney, C. E. (2008). Behavioral Treatment of Insomnia. CRC Press eBooks. https://doi.org/10.3109/9781420019926-8
180. Edinoff, A. N., Wu, N. W., Ghaffar, Y. T., Prejean, R., Gremillion, R., Cogburn, M., Chami, A. A., Kaye, A. M., & Kaye, A. D. (2021). Zolpidem: Efficacy and Side Effects for Insomnia. Health psychology research. https://doi.org/10.52965/001c.24927
181. Egbuta, C., & Mason, K. P. (2021). Current State of Analgesia and Sedation in the Pediatric Intensive Care Unit. Journal of Clinical Medicine. https://doi.org/10.3390/jcm10091847
182. Elhassan, N. M., Al‐Salihy, Z., Bushra, M., Sanabel, A.-A., Albobaly, Y., Eltorki, Y., & Alabdulla, M. (2018). Use of Benzodiazepines and Hypnotic Medications in Psychiatry Older Adult Outpatients. International Journal of Case Reports. https://doi.org/10.28933/ijcr-2018-11-1006
183. Elliot, G. T. (1991). TWO CASES OF DERMATITIS HERPETIFORMIS DEVELOPING AFTER SEVERE MENTAL EMOTION AND SHOCK. Archives of Dermatology. https://doi.org/10.1001/archderm.1991.01680080062003
184. Ensalada, L. H., Brigham, C. R., & Kertay, L. (2018). Somatization. AMA guides newsletter. https://doi.org/10.1001/amaguidesnewsletters.2018.julaug03
185. Erman, M. K. (2006). Influence of pharmacokinetic profiles on safety and efficacy of hypnotic medications. The Journal of Clinical Psychiatry.
186. Erman, M. K. (2006). Influence of Pharmacokinetic Profiles on Safety and Efficacy of Hypnotic Medications. The Primary Care Companion To The Journal of Clinical Psychiatry.
187. Erro, R. (2019). Familial Paroxysmal Nonkinesigenic Dyskinesia.
188. Erstad, B. L., & Cotugno, C. L. (1995). Management of alcohol withdrawal. American Journal of Health-System Pharmacy. https://doi.org/10.1093/ajhp/52.7.697
189. Ertem, D. H., Maner, F., & Köksal, A. (2013). Text messaging as a new compulsive behavior in a patient with <scp>P</scp>arkinson's disease. Psychiatry and Clinical Neurosciences. https://doi.org/10.1111/pcn.12015
190. Eschalier, A., Fialip, J., Aumaître, O., Maradeix, B., Dordain, G., & Lavarenne, J. (1987). Benzodiazepine withdrawal seizures: analysis of 48 case reports.. PubMed.
191. Eskander, F. S. L., Hakim, K. Y. K., Ibrahim, D., & ElMallah, W. (2021). Incidence Of Post-Operative Delirium In Geriatric Patients Undergoing Hip Replacement Surgery Using Pre-Operative Haloperidol. QJM. https://doi.org/10.1093/qjmed/hcab086.109
192. Evans, D., Levene, M. I., & Tsakmakis, M. (2007). Anticonvulsants for preventing mortality and morbidity in full term newborns with perinatal asphyxia. Cochrane database of systematic reviews. https://doi.org/10.1002/14651858.cd001240.pub2
193. Evans, R. W. (2008). Treating migraine in the emergency department. BMJ. https://doi.org/10.1136/bmj.39560.696748.80
194. Fabrazzo, M., Fuschillo, A., Perris, F., & Catapano, F. (2019). The unmasking of hidden severe hyponatremia after long-term combination therapy in exacerbated bipolar patients. International Clinical Psychopharmacology. https://doi.org/10.1097/yic.0000000000000265
195. Faden, J., & Maymind, E. (2025). Long‐Acting Injectables: A Strategy to Mitigate Nonadherence in Bipolar Disorder. Bipolar Disorders. https://doi.org/10.1111/bdi.70005
196. Fama, J. M., & Wilhelm, S. (2010). Obsessions. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0616
197. Farrell, B., Hughes, L., Neutel, I., & Babcock, K. (2003). Facilitating the Process of Medication Re-evaluation and Withdrawal in the Long-Term Institutionalized Population: The Example of Cisapride. The Canadian Journal of Hospital Pharmacy. https://doi.org/10.4212/cjhp.v56i1.407
198. Fasano, A., Elia, A. E., Soleti, F., Guidubaldi, A., & Bentivoglio, A. R. (2006). Punding and computer addiction in Parkinson's disease. Movement Disorders. https://doi.org/10.1002/mds.20787
199. Fava, G. A. (2011). DB02-01 - Drug treatment is not necessary for maintenance treatment of depression. European Psychiatry. https://doi.org/10.1016/s0924-9338(11)73495-2
200. Fava, G. A., Benasi, G., & Cosci, F. (2017). The Potential Role of Iatrogenic Comorbidity in the Interaction between Pharmacotherapy and Psychotherapy in Anxiety Disorders. Verhaltenstherapie. https://doi.org/10.1159/000460826
201. Fava, M., & Rush, A. J. (2006). Current Status of Augmentation and Combination Treatments for Major Depressive Disorder: A Literature Review and a Proposal for a Novel Approach to Improve Practice. Psychotherapy and Psychosomatics. https://doi.org/10.1159/000091771
202. FAVRE, I. M., Véran, O., Payen, I., & Vercueil, L. (2011). Transient Epileptic Amnesia: a case report and a reappraisal. Gériatrie et Psychologie Neuropsychiatrie du Viellissement. https://doi.org/10.1684/pnv.2011.0254
203. Ferini‐Strambi, L., Sforza, M., Poletti, M., Giarrusso, F., & Galbiati, A. (2017). Daytime sleepiness: more than just Obstructive Sleep Apnea (OSA). La Medicina del lavoro. https://doi.org/10.23749/mdl.v108i4.6497
204. Ferraro, T. N., Fischer, B. D., & Buono, R. J. (2020). Genetic Causes of Medication-Resistant Epilepsy. Cambridge University Press eBooks. https://doi.org/10.1017/9781316492376.009
205. Fiar, Z., Hroudov, J., & Raboch, J. (2012). Neurotransmission in Mood Disorders. InTech eBooks. https://doi.org/10.5772/31831
206. Fingerhood, M. (2020). Sedatives. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197506172.003.0005
207. Fink, M. (1993). Post-ECT Delirium.. PubMed.
208. Fink, M. (2010). Depressive Mood Disorders. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780195365740.003.0009
209. Fink, M. (2010). Movement Disorders. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780195365740.003.0011
210. Finnegan, P., Murphy, M., & O’Connor, C. (2022). Reinventing the wheal: A review of online misinformation and conspiracy theories in urticaria. Clinical & Experimental Allergy. https://doi.org/10.1111/cea.14246
211. Fischer, T., Agar, M., Hosie, A., & Teodorczuk, A. (2020). Unpacking agitation in practice: a call for greater precision. Age and Ageing. https://doi.org/10.1093/ageing/afaa110
212. Fisher, A. D., Bandini, E., Casale, H., & Maggi, M. (2011). Paraphilic Disorders: Diagnosis and Treatment. https://doi.org/10.1002/9781119963820.ch8
213. Fitzgerald, C., & Patten, S. B. (2008). Is Multiple Sclerosis Patient Depressed, Stressed, or Both? How to Sort through Overlapping Symptoms and Provide Appropriate Treatment. Current psychiatry.
214. Flaer, P. J. (2015). Co-Morbidity of Obsessive-Compulsive Disorder (OCD) and Chronic Depression. Clinical and Experimental Medical Letters.
215. Flaer, P. J., & AlRubaie, M. (2019). Cannabidiol (CBD): An Innovative Pharmacological Treatment for Obsessive Compulsive Disorder (OCD). https://doi.org/10.37591/rrjon.v7i1.965
216. FM, P., & FP, J. (2015). Persistent Genital Arousal Disorder as a Dissociative Trauma Related Condition Treated with Brainspotting A Successful Case Report. International Journal of School and Cognitive Psychology. https://doi.org/10.4172/2469-9837.1000s1-002
217. Foo, Y.-C., Tam, C. L., Ehsan, S. D., & Cheah, J. (2012). Impacts of Drug Use on Memory. AUSTRALIAN JOURNAL OF BASIC AND APPLIED SCIENCES.
218. Foreman, J. H. (2012). The effects of prolonged endurance exercise on the neurological system in horses. Comparative Exercise Physiology. https://doi.org/10.3920/cep11019
219. Fowler, A. W. (2003). Patients need comfort and control in beds and chairs. BMJ. https://doi.org/10.1136/bmj.327.7427.1349-b
220. Fox, C., Jimoh, F. O., & Cross, J. (2018). Intervention to prevent, delay or reduce frailty in community-living older adults..
221. Franken, I. H. A., & Wiers, R. W. (2013). [Motivational processes in addiction: the role of craving, salience and attention].. PubMed.
222. Franklin, J. (1995). Addiction Medicine. JAMA. https://doi.org/10.1001/jama.1995.03520450026012
223. Funk, S. (2013). [Pharmacological treatment in alcohol-, drug- and benzodiazepine-dependent patients - the significance of trazodone].. PubMed.
224. Gagliardi, B., Luscher, V., Monin, Y., Kherad, O., & Coronado, L. (2021). [Sleep disturbances related to nocturnal nuisances in elderly inpatients].. PubMed.
225. Galanter, M. (2014). Network Therapy for Substance Use Disorders. American Psychiatric Publishing eBooks. https://doi.org/10.1176/appi.books.9781585625048.gg60
226. Galima, S. V., Vogel, S. R., & Kowalski, A. W. (2020). Seasonal Affective Disorder: Common Questions and Answers..
227. Gallo, A. T., & Hulse, G. (2022). Hyperbolic dose reduction of escitalopram mitigates withdrawal syndrome: A case report. Psychiatry Research Case Reports. https://doi.org/10.1016/j.psycr.2022.100009
228. García, R. G., Alvarez, M. R., & Arturo, F. (2010). Cefalea por uso excesivo de medicamentos: implicaciones clínicas y terapéuticas Medication over use headache: clinical and therapeutic implications.
229. Garrabé, J., & Cousin, F. (2012). Acute and transient psychotic disorders. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199696758.003.0081
230. Geiser, M., Good, J., & Guinchat, V. (2024). Pregabalin treatment in a 30-year-old patient with Bainbridge-Ropers syndrome: a case-report. Frontiers in Psychiatry. https://doi.org/10.3389/fpsyt.2024.1502773
231. Genazzani, A. D., Ricchieri, F., Lanzoni, C., Strucchi, C., & Jasonni, V. M. (2006). Diagnostic and Therapeutic Approach to Hypothalamic Amenorrhea. Annals of the New York Academy of Sciences. https://doi.org/10.1196/annals.1365.009
232. Girolamo, G. D., Dagani, J., Purcell, R., Cocchi, A., & McGorry, P. D. (2011). Age of onset of mental disorders and use of mental health services: needs, opportunities and obstacles. Epidemiology and Psychiatric Sciences. https://doi.org/10.1017/s2045796011000746
233. Glasgow, H. B., Burkholder, J. M., Schmechel, D. E., Tester, P. A., & Rublee, P. A. (1995). Insidious effects of a toxic estuarine dinoflagellate on fish survival and human health. Journal of Toxicology and Environmental Health. https://doi.org/10.1080/15287399509532051
234. Glueck, B. (2017). Psychophysiological Correlates of Meditation: Eeg Changes During Meditation *. Routledge eBooks. https://doi.org/10.4324/9780203785843-56
235. Gomathy, S. B., Saini, A., Gupta, A., Vishnu, V. Y., Singh, M. B., Bhatia, R., Srivastava, M. P., Radhakrishnan, D. M., Srivastava, A. K., & Rajan, R. (2024). A rare yet treatable case of paroxysmal kinesigenic dyskinesia. Annals of Movement Disorders. https://doi.org/10.4103/aomd.aomd_28_23
236. Gong, M., Tang, Q., Tan, S., & Hu, X. (2024). [Research Progress in the Effect of Exercise Intervention on Sleep Disorders and the Mechanisms Involved].. PubMed. https://doi.org/10.12182/20240160404
237. González, L., Nwugbana, I., Patel, R., Lombardo, M., & Korenis, P. (2015). Strategies for Effective Management of Intellectually Disabled Patients on the Psychiatric Inpatient Unit. Journal of Intellectual Disability - Diagnosis and Treatment. https://doi.org/10.6000/2292-2598.2015.03.02.7
238. Gottlieb, S., & Friedman, S. B. (1991). Conduct Disorders in Children and Adolescents. Pediatrics in Review. https://doi.org/10.1542/pir.12.7.218
239. Graddy, R., & Rastegar, D. A. (2025). Stimulants. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197796207.003.0008
240. Grannell, L. (2020). Drug interaction resources: mind the gaps. Australian Prescriber. https://doi.org/10.18773/austprescr.2020.005
241. Grant, I., Sacktor, N., & McArthur, J. C. (2005). HIV neurocognitive disorders. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780198526100.003.0035
242. Gray, A. (2003). Quality use of medicines: The patient with Acute Cough. South African Family Practice. https://doi.org/10.4102/safp.v45i8.1896
243. Gregorowski, C., Seedat, S., & Jordaan, G. P. (2013). A clinical approach to the assessment and management of co-morbid eating disorders and substance use disorders. BMC Psychiatry. https://doi.org/10.1186/1471-244x-13-289
244. Greist, J. H., Bandelow, B., Hollander, E., Marazziti, D., Okasha, A., Zohar, J., Allgulander, C., Cassano, G. B., Pollack, M. S., & Ameringen, M. V. (2003). Recommendations for the Long-Term Treatment of Anxiety Disorders.
245. Greydanus, D. E., Calles, J. L., & Patel, D. R. (2008). Anxiety disorders. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511544705.007
246. Groppa, S., González‐Escamilla, G., Tinkhauser, G., Baqapuri, H. I., Sajonz, B., Wiest, C., Pereira, J. B., Herz, D. M., Dold, M., Bange, M., Ciolac, D., Almeida, V., Neuber, J., Mîrzac, D., Martín‐Rodríguez, J. F., Dresel, C., Muthuraman, M., Gomez, A. D. A., Navas, M., ... Coenen, V. A. (2023). Perspectives of Implementation of Closed-Loop Deep Brain Stimulation: From Neurological to Psychiatric Disorders. Stereotactic and Functional Neurosurgery. https://doi.org/10.1159/000535114
247. Grossman, W. I. (1991). Pain, Aggression, Fantasy, and Concepts of Sadomasochism. The Psychoanalytic Quarterly. https://doi.org/10.1080/21674086.1991.11927300
248. Grosso, S., Cioni, M., Pucci, L., Morgese, G., & Balestri, P. (1999). Selective mutism, speech delay, dysmorphisms, and deletion of the short arm of chromosome 18: a distinct entity?. Journal of Neurology Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp.67.6.830
249. Group, M. T., Mackway‐Jones, K., Marsden, J., & Windle, J. (2006). Discriminator Dictionary. https://doi.org/10.1002/9780470757321.oth3
250. Guineau, M. G., Voshaar, R. C. O., & Hendriks, G.-J. (2024). [Intensive exposure treatment for obsessive compulsive disorder in old age.]. PubMed.
251. Gullapalli, D., Belak, Z. A., Marte-Grau, A. C., Bollu, M., Reddy, P., & Bobba, R. K. (2009). GELASTIC PRESYNCOPE: AN UNUSUAL MANIFESTATION IN AN ELDERLY PATIENT. Journal of the American Geriatrics Society. https://doi.org/10.1111/j.1532-5415.2009.02208.x
252. Gutiérrez-Arias, R., González-Mondaca, C., Marinkovic-Riffo, V., Ortiz-Puebla, M., Paillán-Reyes, F., & Serón, P. (2022). Considerations for ensuring safety during telerehabilitation of people with stroke. A protocol for a scoping review. https://doi.org/10.37766/inplasy2022.9.0104
253. Guy, A., Brown, M., Lewis, S., & Horowitz, M. (2020). The ‘patient voice’: patients who experience antidepressant withdrawal symptoms are often dismissed, or misdiagnosed with relapse, or a new medical condition. Therapeutic Advances in Psychopharmacology. https://doi.org/10.1177/2045125320967183
254. Güleç, H., Babayiğit, M., Kurtay, A., Şahap, M., Ulus, F., Tutal, Z. B., & Horasanlı, E. (2014). Seizure due to multiple drugs intoxication: a case report. Brazilian Journal of Anesthesiology (English Edition). https://doi.org/10.1016/j.bjane.2014.02.013
255. Güngörmüş, Z., & Özgüç, S. (2025). Psychosocial problems observed in older adults after disaster. Psychogeriatrics. https://doi.org/10.1111/psyg.70001
256. Hamed, S. A. (2017). The auditory and vestibular toxicities induced by antiepileptic drugs. Expert Opinion on Drug Safety. https://doi.org/10.1080/14740338.2017.1372420
257. Hammerman, O., Ifergane, G., & Ezra, Y. (2017). [PSYCHO-MEDICAL ASPECTS OF PRIMARY HEADACHES].. PubMed.
258. Hao, Y., Controzzi, M., Cipriani, C., Popović, D. B., Yang, X., Chen, W., Zheng, X., & Carrozza, M. C. (2013). Controlling hand-assistive devices: utilizing electrooculography as a substitute for vision. IEEE Robotics & Automation Magazine. https://doi.org/10.1109/mra.2012.2229949
259. Harding, S. (2005). Continuing Professional Development Managing delirium in older people.
260. Harwell, M. (2019). Working Through the Unconscious Assumption of Neglect. Psychoanalytic Inquiry. https://doi.org/10.1080/07351690.2019.1623623
261. Hatcher-Kay, C., & King, C. A. (2003). Depression and Suicide. Pediatrics in Review. https://doi.org/10.1542/pir.24-11-363
262. Hatcher-Kay, C., & King, C. A. (2003). Depression and Suicide. Pediatrics in Review. https://doi.org/10.1542/pir.24.11.363
263. Hayati, R. (2019). Terapi Gerak pada Anak Sindrom Desintegratif.
264. Hayati, R. (2019). Token Ekonomi pada Anak dengan Gangguan ADHD. https://doi.org/10.29406/eksis.v1i2.1690
265. Hayes, A., & Lingford‐Hughes, A. (2023). Drug Use, Addiction, Tolerance, Withdrawal and Relapse. Cambridge University Press eBooks. https://doi.org/10.1017/9781911623137.058
266. Hechtman, L. (1991). Resilience and Vulnerability in Long Term Outcome of Attention Deficit Hyperactive Disorder. The Canadian Journal of Psychiatry. https://doi.org/10.1177/070674379103600606
267. Heinrich, J., Houtman, I., Miedema, M., Jettinghoff, K., Starren, A., Gort, J., Wulder, J., & Wubbolts, S. (2005). Fatigue in the shipping industry. TNO eBooks.
268. Hernández, G., García, L. H., Baez, I. C., Rodrigo, A. M., Torres, C. D., Gómez-Juanes, R., & Pérez, P. G. (2023). Antiandrogenic treatment of obsessive compulsive neurosis: A case review. European Psychiatry. https://doi.org/10.1192/j.eurpsy.2023.1961
269. Hernández, M., ESQUIVEL, N., & López, M. (2014). Fisiopatología, diagnóstico diferencial y tratamiento de la apnea emotiva grave: A propósito de un caso clínico. Revista chilena de pediatría. https://doi.org/10.4067/s0370-41062014000400012
270. Hertz, L., Song, D., Li, B., Du, T., Xu, J., Gu, L., Chen, Y., & Liang, P. (2014). Signal Transduction in Astrocytes during Chronic or Acute Treatment with Drugs (SSRIs, Antibipolar Drugs, GABA-ergic Drugs, and Benzodiazepines) Ameliorating Mood Disorders. Journal of Signal Transduction. https://doi.org/10.1155/2014/593934
271. Higgins, A. (2010). Antidepressant-associated sexual dysfunction: impact, effects, and treatment. Drug Healthcare and Patient Safety. https://doi.org/10.2147/dhps.s7634
272. Hirschfeld, R. M. A., Calabrese, J. R., Frye, M. A., Lavori, P. W., Sachs, G., Thase, M. E., & Wagner, K. D. (2007). Defining the clinical course of bipolar disorder: response, remission, relapse, recurrence, and roughening.. PubMed.
273. Hlodak, J., Gecková, A. M., Veselská, Z. D., & Feketeová, E. (2025). The burden of narcolepsy symptoms from patients’ perspective: a narrative qualitative study. Sleep And Breathing. https://doi.org/10.1007/s11325-025-03407-y
274. Hocker, S. E., Wijdicks, E. F. M., & Rabinstein, A. A. (2013). Refractory status epilepticus: new insights in presentation, treatment, and outcome. Neurological Research. https://doi.org/10.1179/1743132812y.0000000128
275. Holiman, J. J., Kieran, K., & Bader, C. S. (2022). Sad or just unconcerned?. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197521670.003.0021
276. Holloman, L. C., & Marder, S. R. (1997). Management of acute extrapyramidal effects induced by antipsychotic drugs. American Journal of Health-System Pharmacy. https://doi.org/10.1093/ajhp/54.21.2461
277. Hong, I. S., & Bishop, J. R. (2014). Geriatric Patients: Choose Wisely: Age-Related Physiologic Changes, Risk of Adverse Effects Guide Your Prescribing. Current psychiatry.
278. Hopkins, R. O., & Brett, S. J. (2005). Chronic neurocognitive effects of critical illness. Current Opinion in Critical Care. https://doi.org/10.1097/01.ccx.0000166399.88635.a5
279. Hoque, R., & Chesson, A. L. (2010). Pharmacologically induced/exacerbated restless legs syndrome, periodic limb movements of sleep, and REM behavior disorder/REM sleep without atonia: literature review, qualitative scoring, and comparative analysis.. PubMed.
280. Horn, J. B., Zandbergen, E., Koelman, J., & Hijdra, A. (2008). Prognosis for patients in a coma following cardiopulmonary resuscitation.
281. House, J. S. (1987). Chronic stress and chronic disease in life and work: Conceptual and methodological issues. Work & Stress. https://doi.org/10.1080/02678378708258494
282. Housley, S. B., Patel, D., Nyabuto, E., & Reynolds, R. M. (2021). Spinal cord detethering without laminectomy or laminotomy. Surgical Neurology International. https://doi.org/10.25259/sni_942_2021
283. Howard, R., Tan, S. V., & Z’Graggen, W. J. (2008). Weakness on the intensive care unit. Practical Neurology. https://doi.org/10.1136/jnnp.2008.157263
284. Howland, R. H. (2014). Delirium and Its Prevention with Melatonergic Drugs. Journal of Psychosocial Nursing and Mental Health Services. https://doi.org/10.3928/02793695-20140423-02
285. Hsieh, M. T., Peng, W., Wu, C., Ng, K., Cheng, C. Y., & Xu, H. (2010). None. Planta Medica. https://doi.org/10.1055/s-002-20741
286. Huang, K., & Tsai, S. (2012). The importance of measuring impulsiveness in patients with addiction problems. Journal of the Chinese Medical Association. https://doi.org/10.1016/j.jcma.2012.10.003
287. Huis, K. (2014). Suvremeno liječenje paničnog poremećaja.
288. Hutomo, Y. (2024). Hypnothereapy Intervention for the Treatment of Insomnia in A 26 Years-Old Woman with General Anxiety Disorder: A Case Report. Enrichment Journal of Multidisciplinary Research and Development. https://doi.org/10.55324/enrichment.v2i8.225
289. Hybels, C. F., Blazer, D. G., & Steffens, D. C. (2006). Partial remission. A common outcome in older adults treated for major depression.. PubMed.
290. Ilbeigi, M. S., Davidson, M., & Yarmush, J. (1998). An Unexpected Arousal Effect of Etomidate in a Patient on High-dose Steroids . Anesthesiology. https://doi.org/10.1097/00000542-199812000-00045
291. Isobe, T., Sato, H., Goto, T., Yako, T., Yoshida, K., & Hashimoto, T. (2019). Supplementary Material for: Long-Term Suppression of Disabling Tremor by Thalamic Stimulation in a Patient with Spinocerebellar Ataxia Type 2. Figshare. https://doi.org/10.6084/m9.figshare.10331774
292. Isometsä, E., Kinnunen, E., Kivekäs, T., Koponen, H., Lappalainen, J., Lindfors, O., Marttunen, M., Pirkola, S., Jousilahti, P., & Tuunainen, A. (2015). [Update on Current Care Guideline: Depression].. PubMed.
293. Ivada, P. F., Ardani, I. G. A. I., Lesmana, C. B. J., Windiani, I. G. A. T., Adnyana, I. G. A. N. S., & Fithriyah, I. (2022). Quality of life of pediatric patients experiencing organic depressive disorder with Juvenile Idiopathic Arthritis. International journal of health & medical sciences. https://doi.org/10.21744/ijhms.v5n4.1994
294. Jablensky, A. (2012). Course and outcome of schizophrenia and their prediction. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199696758.003.0078
295. Jarrett, R. B., Schaffer, M., McIntire, D. D., Witt-Browder, A., Kraft, D., & Risser, R. C. (1999). Treatment of Atypical Depression With Cognitive Therapy or Phenelzine. Archives of General Psychiatry. https://doi.org/10.1001/archpsyc.56.5.431
296. Jay, G. W. (2013). Interdisciplinary Treatment of Chronic Noncancer Pain. CRC Press eBooks. https://doi.org/10.3109/9781439824894-12
297. Jehanzeb, S., & Javaid, A. (2025). The Life-Changing Diagnosis in a Patient With Treatment-Resistant Depression, From Darkness to Light and Healing. BJPsych Open. https://doi.org/10.1192/bjo.2025.10735
298. Jellinger, K. A. (2025). Parkinsonism associated with prolonged unresponsive wakefulness syndrome after blunt head injury: a clinico-pathological study.. PubMed. https://doi.org/10.17879/freeneuropathology-2025-5982
299. Jeon, H. J. (2023). Clinical presentation, diagnosis, and treatment of sleep disorders in adolescents. Journal of Korean Medical Association. https://doi.org/10.5124/jkma.2023.66.4.258
300. Jl, H., & Fn, S. (1981). Drug interference with laboratory value interpretation: A review.. PubMed.
301. Judd, L. L., Schettler, P. J., Brown, E. S., Wolkowitz, O. M., Sternberg, E. M., Bender, B. G., Bulloch, K., Cidlowski, J. A., Kloet, E. R. D., Fardet, L., Joëls, M., Leung, D. Y., McEwen, B. S., Roozendaal, B., Rossum, E. F. C. V., Ahn, J., Brown, D. W., Plitt, A., & Singh, G. (2014). Adverse Consequences of Glucocorticoid Medication: Psychological, Cognitive, and Behavioral Effects. American Journal of Psychiatry. https://doi.org/10.1176/appi.ajp.2014.13091264
302. Kaggwa, M. M., Nkola, R., Najjuka, S. M., Bongomin, F., Ashaba, S., & Mamun, M. A. (2021). Extrapyramidal Side Effects in a Patient with Alcohol Withdrawal Symptoms: A Reflection of Quality of the Mental Health Care System. Risk Management and Healthcare Policy. https://doi.org/10.2147/rmhp.s314451
303. Kales, A., & Kales, J. D. (1983). Sleep Laboratory Studies of Hypnotic Drugs. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/00004714-198304000-00038
304. Kales, A., Soldatos, C. R., Bixler, E. O., & Kales, J. D. (1983). Early Morning Insomnia with Rapidly Eliminated Benzodiazepines. Science. https://doi.org/10.1126/science.6131538
305. Kales, A., Soldatos, C. R., Bixler, E. O., & Kales, J. D. (1983). Rebound Insomnia and Rebound Anxiety: A Review. Pharmacology. https://doi.org/10.1159/000137794
306. Kalivas, P. W. (2003). Development and Expression of Behavioral Sensitization. Humana Press eBooks. https://doi.org/10.1007/978-1-59259-343-9_9
307. Kalivas, P. W., Toda, S., Bowers, M. S., Baker, D. L., & Ghasemzadeh, M. B. (2003). The Temporal Sequence of Changes in Gene Expression by Drugs of Abuse. Humana Press eBooks. https://doi.org/10.1385/1-59259-358-5:03
308. Kanchanatawan, B., & Kasantikul, D. (2007). Antipsychotic-induced tardive movement disorders: a series of twelve cases.. PubMed.
309. Karssemeijer, E. G., Heijden, C. D. V. D., Wolters, T. L. C., Boekhorst, B. T., Avest, M. T., & Kramers, C. (2021). [Don't stop medication too abruptly: advice about the discontinuation of medication]..
310. Karssemeijer, E. G., Heijden, C. D. V. D., Wolters, T. L. C., Boekhorst, B. T., Avest, M. T., & Kramers, C. (2021). [Don't stop medication too abruptly: advice about the discontinuation of medication].. PubMed.
311. Katz, N., Fleming, J., Keren, N., Lightbody, S., & Maeir, A. (2002). Unawareness and/or Denial of Disability: Implications for Occupational Therapy Intervention. Canadian Journal of Occupational Therapy. https://doi.org/10.1177/000841740206900504
312. Kauppila, L. A., Amorim, I., Bentes, C., & Peralta, A. R. (2018). Trazodone: A New Antiepileptic Drug for Dravet Syndrome?. International Journal of Epilepsy. https://doi.org/10.1055/s-0039-1677783
313. Keck, P. E. (2003). The management of acute mania. BMJ. https://doi.org/10.1136/bmj.327.7422.1002
314. Keller, M. (1993). The difficult depressed patient in perspective.. PubMed.
315. Kennedy, J. E., Jaffee, M. S., & Cooper, D. (2013). Posttraumatic Stress Disorder. American Psychiatric Publishing eBooks. https://doi.org/10.1176/appi.books.9781585625154.da08
316. Khandelwal, S., & Desai, M. (2024). Prevalence of Fatigue Among Female Academicians. International Journal of Health Sciences and Research. https://doi.org/10.52403/ijhsr.20240324
317. Kim, B. (2019). Pharmacotherapy for attention-deficit/hyperactivity disorder. Journal of Korean Medical Association. https://doi.org/10.5124/jkma.2019.62.1.49
318. Kim, D., Kwon, O. Y., Kim, Y.-S., Hye, K. S., Son, S., Park, K., Choi, N. C., & Lim, B. H. (2004). A Case of Bilateral Sciatic Neuropathy Caused by Lotus Position. Journal of the Korean Neurological Association.
319. Kim, D., Oh, S., & Kim, O. J. (2007). A Case of Lamotrigine-Induced Excessive Involuntary Eye Blinking. Journal of Clinical Neurology. https://doi.org/10.3988/jcn.2007.3.2.93
320. Kintz, P., Blanchot, A., Farrugia, A., & Goullé, J. (2025). [Toxicological aspects of chemical submission].. PubMed.
321. Kirilly, E., Gonda, X., Juhász, G., & Bagdy, G. (2013). Nem pszichiátriai gyógyszerek szorongást és depressziót kiváltó mellékhatásai | Anxiogenic and depressogenic side-effects of non-psychiatric drugs.
322. Kirshbaum, M. (2011). Pharmacologic Treatments for Fatigue Associated With Palliative Care. Clinical journal of oncology nursing. https://doi.org/10.1188/11.cjon.438-439
323. Kitching, D. (2015). Depression in dementia. Australian Prescriber. https://doi.org/10.18773/austprescr.2015.071
324. Klega, A. E., & Keehbauch, J. (2018). Stimulant and Designer Drug Use: Primary Care Management.. PubMed.
325. Klimek, A. (2010). Physiological Background of Muscular Pain During Skiing and Delayed Muscle Soreness after Skiing. Journal of Human Kinetics. https://doi.org/10.2478/v10078-010-0007-4
326. Knapen, J., Vancampfort, D., Schoubs, B., Probst, M.-T., Sienaert, P., Haake, P., Peuskens, J., & Pieters, G. (2009). Exercise for the Treatment of Depression. The Open Complementary Medicine Journal. https://doi.org/10.2174/1876391x00901010078
327. Koenigsberg, H. W. (1997). Integrating psychotherapy and pharmacotherapy in the treatment of borderline personality disorder. In Session Psychotherapy in Practice. https://doi.org/10.1002/(sici)1520-6572(199722)3:2<39::aid-sess4>3.0.co;2-3
328. Kolla, B., & Hocker, S. E. (2021). Substance Use Disorders. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197512166.003.0045
329. Koller, W. C., Weiner, W. J., Perlik, S., Nausieda, P. A., Goetz, C. G., & Klawans, H. L. (1981). Complications of chronic levodopa therapy. Neurology. https://doi.org/10.1212/wnl.31.4.473
330. Koller, W. C., Weiner, W. J., Perlik, S., Nausieda, P. A., Goetz, C. G., & Klawans, H. L. (1981). Complications of chronic levodopa therapy. Neurology. https://doi.org/10.1212/wnl.31.4_part_2.473
331. Koob, G. F. (2013). Neurocircuitry of Addiction: A brain reward deficit, stress surfeit and executive function disorder. Suchttherapie. https://doi.org/10.1055/s-0033-1351398
332. Koob, G. F. (2014). PL1 * ADDICTION AS A REWARD, STRESS AND EXECUTIVE FUNCTION DISORDER. Alcohol and Alcoholism. https://doi.org/10.1093/alcalc/agu051.1
333. Koob, G. F. (2020). Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development. Pharmacological Reviews. https://doi.org/10.1124/pharmrev.120.000083
334. Koot, S., Adriani, W., Bos, R. V. D., & Laviola, G. (2008). Home cage testing of impulsivity.
335. Kopp, S., & Gillberg, C. (2022). [Symptoms, diagnostic process and outcome in girls and women with ADHD].. PubMed.
336. Kornstein, S. G., McIntyre, R. S., Thase, M. E., & Boucher, M. (2014). Desvenlafaxine for the treatment of major depressive disorder. Expert Opinion on Pharmacotherapy. https://doi.org/10.1517/14656566.2014.923403
337. Koster, S., Hensens, A. G., Schuurmans, M. J., & Palen, J. V. D. (2011). Consequences of Delirium After Cardiac Operations. The Annals of Thoracic Surgery. https://doi.org/10.1016/j.athoracsur.2011.07.006
338. Kotade, K. B., Pandit, B. S., Gaware, V. M., Dolas, R. T., Dhamak, K. B., Somwanshi, S. B., Nikam, V. K., & Khadse, A. N. (2011). KNOWING DEPRESSION AND PHARMACOLOGICAL, NON-PHARMACOLOGICAL APPROACHES FOR ITS TREATMENT.
339. Kovalenko, A. L., Sinenchenko, A. G., & Lodyagin, A. N. (2022). [CLINICAL CASE OF ACUTE SEVERE COMBINED POISONING WITH NARCOTIC SUBSTANCES OF DEPENDENT AND PSYCHOSTIMULATING EFFECTS].. PubMed.
340. Krejcie, T. C., & Avram, M. J. (2011). When Duzitol Does Not Do It All. Anesthesia & Analgesia. https://doi.org/10.1213/ane.0b013e3182251509
341. Krsti, J., & Ili, T. V. (2014). Switch to hypomania induced by repetitive transcranial magnetic stimulation and partial sleep deprivation added to antidepressant: A case report Hipomanija indukovana primenom repetitivne transkranijalne magnetne stimulacije i parcijalne deprivacije spavanja kod bolesnika na terapiji antidepresivima.
342. Kulkarni, S., Yeshaswini, M. C., & Durai, S. (2025). THYROID STORM OR STORM BREWING? A CASE OF LEVOTHYROXINE OVERDOSE WITH DELAYED PRESENTATION. International Journal of Scientific Research. https://doi.org/10.36106/ijsr/1509030
343. Kumar, P. S., Krishnan, A., & Suresh, R. (2019). Escitalopram-induced extrapyramidal symptoms. Indian Journal of Psychiatry. https://doi.org/10.4103/psychiatry.indianjpsychiatry_331_18
344. Kumar, S., & Browne, M. O. (2003). What are the effects of drug treatments for panic disorder?. Evidence-Based Mental Health. https://doi.org/10.1136/ebmh.6.2.34
345. Kusumadewi, A. F. (2020). Case Report: Magic Mushroom (Psilocybe Cubensis) Intoxication. Archives of The Medicine and Case Reports. https://doi.org/10.37275/amcr.v1i2.13
346. Kuzminov, V. (2019). he dependence of the clinical picture of acute psychosis connected with alcohol withdrawal from the forms of alcohol consumption. Ukrains kyi Visnyk Psykhonevrolohii. https://doi.org/10.36927/2079-0325-v27-is1-2019-16
347. Lader, M., & Morton, S. V. (1992). A pilot study of the effects of flumazenil on symptoms persisting after benzodiazepine withdrawal. Journal of Psychopharmacology. https://doi.org/10.1177/026988119200600303
348. Lalithaa, K., & Kathiravan, J. (2020). Effectiveness of homoeopathic medicines in illness anxiety disorders among young adults. International Journal of Homoeopathic Sciences. https://doi.org/10.33545/26164485.2020.v4.i2b.154
349. Landry, M. J., Smith, D. E., McDuff, D., & Baughman, O. L. (1992). Benzodiazepine dependence and withdrawal: identification and medical management.. PubMed.
350. Langguth, B., Bär, R., Wodarz, N., Wittmann, M., & Laufkötter, R. (2011). Paradoxical Reaction in ADHD. Deutsches Ärzteblatt international. https://doi.org/10.3238/arztebl.2011.0541a
351. Lavin, M. (2010). Voyeurism. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy1030
352. Ledezma, C., Soto, K., & Suárez, M. I. (2015). Depresión en el adulto mayor en Costa Rica: un problema social. Revista Hispanoamericana de Ciencias de la Salud.
353. Lee, H., Kim, J., Lee, H.-S., Jo, Y.-H., Ko, J.-A., In, S., & Lee, J.-B. (2023). MS Fragmentation of ALD-52 with GC-MS and LC-QTOF. Korean Journal of Forensic Science. https://doi.org/10.53051/ksfs.2023.24.1.2
354. Lee, J. H., Kim, H. J., Lee, H. W., & Joo, E. Y. (2006). Adult-onset Sleep Related Rhythmic Movement Disorder. Journal of Korean Sleep Research Society. https://doi.org/10.13078/jksrs.06016
355. LEHMAN, M., Foster, C., & Keul, J. (1993). Overtraining in endurance athletes: a brief review. Medicine & Science in Sports & Exercise. https://doi.org/10.1249/00005768-199307000-00015
356. Leiblum, S. R. (2003). Arousal disorders in women: complaints and complexities. The Medical Journal of Australia. https://doi.org/10.5694/j.1326-5377.2003.tb05392.x
357. Lejoyeux, M., & Adès, J. (1993). [Psychiatric emergencies in acute alcoholic intoxication].. PubMed.
358. Lepping, P., Huber, M., & Freudenmann, R. W. (2015). How to approach delusional infestation. BMJ. https://doi.org/10.1136/bmj.h1328
359. Levani, Y., Prastya, A. D., & Ramadhani, S. N. (2019). KLEPTOMANIA: MANIFESTASI KLINIS DAN PILIHAN TERAPI. MAGNA MEDICA Berkala Ilmiah Kedokteran dan Kesehatan. https://doi.org/10.26714/magnamed.6.1.2019.31-37
360. Lečić-Toševski, D. M., Pejović-Milovančević, M., Popović-Deušić, S., & Šušić (2007). [Psychiatric aspects of sleep].. PubMed.
361. Li, K., & Loshak, H. (2019). Intravenous Ketamine for Adults with Treatment-Resistant Depression or Post-Traumatic Stress Disorder: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines.
362. Li, Z., Goh, S. N., Teo, Y. W., & How, C. H. (2023). Management of intimate partner abuse. Singapore Medical Journal. https://doi.org/10.4103/singaporemedj.smj-2021-452
363. Liang, Y., & Richelson, E. (2008). Triple reuptake inhibitors: Next-generation antidepressants. Primary psychiatry.
364. Liebowitz, M. R. (1997). Panic disorder as a chronic illness.. PubMed.
365. Liebowitz, M. R., & Hurowitz, G. I. (1993). Antidepressant-induced rapid cycling: six case reports.. PubMed.
366. Lim, H. J., Kwon, Y. J., Lee, J. E., & Cho, S. (2013). Original article : Reconsideration of Psychasthenia- Two Cases. 동의신경정신과학회지.
367. Lim, H., Kwon, Y.-J., Lee, J.-E., & Cho, S. (2013). Reconsideration of Psychasthenia- Two Cases. Journal of Oriental Neuropsychiatry. https://doi.org/10.7231/jon.2013.24.3.245
368. Linzer, S., Chesir, A., Ginsburg, T., & Varas, O. (2017). Stressful Life Events. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190260859.003.0005
369. Lipsey, J. R. (2008). Electroconvulsive Therapy. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780195309430.003.0029
370. Lipton, R. B., & Silberstein, S. D. (2015). Episodic and Chronic Migraine Headache: Breaking Down Barriers to Optimal Treatment and Prevention. Headache The Journal of Head and Face Pain. https://doi.org/10.1111/head.12505_2
371. Liu, G., Slater, N., & Perkins, A. (2017). Epilepsy: Treatment Options.. PubMed.
372. Lobato, E. F. (2013). Persistent hiccup treated by hypnosis. Revista Médica de Minas Gerais. https://doi.org/10.5935/2238-3182.20130040
373. Lobato, E. F. (2013). Soluço persistente tratado por hipnose.
374. Lucassen, P., Ligthart, S. A., Kramers, C., & Speckens, A. (2021). [Why do patients find it difficult to discontinue their medication?]. PubMed.
375. M.E., B., VergelHernández, J., C.A., H., C.S., M., Ospina-Otálvaro, S., J.D., S., P.M., A., J.J., A., Basic, A. C. N. S. R. T. O., & Psychiatry, S. O. M. R. T. O. (2021). Supplementary Material for: Neuropsychiatric Aspects in a Patient Diagnosed with Frontotemporal Dementia: Clinical Case of Low Incidence and Prevalence Disease in Colombia. Figshare. https://doi.org/10.6084/m9.figshare.14932008
376. Madan, A., Frueh, B. C., Fowler, J. C., Stomberg, S., Bradshaw, M. R., Kelly, K. R., Weinstein, B., Luttrell, M., Danner, S. G., & Beidel, D. C. (2020). “Operator syndrome”: A unique constellation of medical and behavioral health-care needs of military special operation forces. The International Journal of Psychiatry in Medicine. https://doi.org/10.1177/0091217420906659
377. Madrid, P. A., Grant, R., Reilly, M. J., & Redlener, N. B. (2006). Challenges in Meeting Immediate Emotional Needs: Short-term Impact of a Major Disaster on Children's Mental Health: Building Resiliency in the Aftermath of Hurricane Katrina. PEDIATRICS. https://doi.org/10.1542/peds.2006-0099u
378. Magyar, M., Hajnal, B., Gyüre, T., & Ertsey, C. (2015). Fájdalomcsillapító-túlhasználathoz társuló fejfájás. Orvosi Hetilap. https://doi.org/10.1556/650.2015.30209
379. Mahato, T. K., Ojha, S. K., Singh, V., & Parihar, S. P. S. (2021). Addiction withdrawal syndrome: Needs medications, education, counselling &amp; support. World Journal of Advanced Research and Reviews. https://doi.org/10.30574/wjarr.2021.12.2.0573
380. mahmoud, F. M. (2024). Nocturnal enuresis in children. American Journal of Medical and Clinical Research & Reviews. https://doi.org/10.58372/2835-6276.1224
381. Maier, L. J., & Schaub, M. P. (2015). The Use of Prescription Drugs and Drugs of Abuse for Neuroenhancement in Europe. European Psychologist. https://doi.org/10.1027/1016-9040/a000228
382. Malenfant, M., Tremblay, S., Laurin, D., & Lefèbvre, J. (2008). L'utilisation du citalopram pour traiter l'agitation et les symptômes psychotiques chez les patients souffrant de démence.
383. Manber, R., Ong, J. C., & Carlyle, E. (2008). Diagnostic Tools for Insomnia. CRC Press eBooks. https://doi.org/10.3109/9781420019926-6
384. Mangum, A., Ling, D., & Velasquez, M. M. (2025). Substance Use Disorders. Social Work. https://doi.org/10.1093/obo/9780195389678-0342
385. Manica, A., Leães, C. G. S., Frey, B. N., & Juruena, M. F. (1999). The role of depression in coronary artery disease. Arquivos Brasileiros de Cardiologia. https://doi.org/10.1590/s0066-782x1999000800012
386. Manschreck, T. C. (1996). Delusional disorder: the recognition and management of paranoia.. PubMed.
387. Marchand, D. K., & Argáez, C. (2021). Codeine for Acute Extremity Pain [Internet].
388. Marchiafava, M., Piccirilli, M., Bedetti, C., Baglioni, A., Menna, M., & Elisei, S. (2018). Effectiveness of serotonergic drugs in the management of problem behaviors in patients with neurodevelopmental disorders.. PubMed.
389. Marcus, L. C., & Plasky, P. (1988). Effects of Drugs on Psychotropic.
390. Maremmani, I., Pacini, M., & Maremmani, A. G. I. (2023). Chronic Psychosis in Dual Disorder Heroin Use Disorder Patients. https://doi.org/10.1007/978-3-031-30093-6_4
391. Maremmani, I., Pacini, M., Lamanna, F., Pani, P., Perugi, G., Deltito, J., Salloum, I. M., & Akiskal, H. S. (2010). Mood Stabilizers in the Treatment of Substance Use Disorders. CNS Spectrums. https://doi.org/10.1017/s1092852900027346
392. Margono, H. M. (2024). Dealing with Loneliness in Hemodialysis Patients: How to Prevent the Detrimental Effects of Loneliness. Jurnal Psikiatri Surabaya. https://doi.org/10.20473/jps.v13is1.62657
393. Maricq, A., Jacques, D., Zdanowicz, N., Marchand, É., Evrard, P., Bulpa, P., & Reynaert, C. (2011). Duloxetine-related panic attacks.. Psychiatria Danubina.
394. Markham, R. A., & Watts, S. (2005). Etiology of Depression in Children.. Journal of instructional psychology.
395. Marković, H., Nikolac, N., Tripković, M., Haluga-Golubović, I., & Čustović, Z. (2012). Connection between Addictive Behavior and Investing on the Stock Market in Croatia.
396. Martı́nez-Raga, J., & López-Cerveró, M. (2019). [Transition of adolescents with attention deficit/hyperactivity disorder. Implications for treatment of adults].. PubMed.
397. Marzal, G. P., Rigual, F. C., Soto, B. B., & Olivares, J. Q. (2015). Psicoestimulantes en la infancia: ¿Medicalización o mejoramiento?.
398. Masdrakis, V. G., Turic, D., & Baldwin, D. S. (2013). Pharmacological Treatment of Social Anxiety Disorder. Modern trends in psychiatry. https://doi.org/10.1159/000351960
399. Masse, C., Bennabi, D., Giustiniani, J., Haffen, É., Sechter, D., & Vandel, P. (2018). Predictors of remission to antidepressants in late-life depression: a systematic review. Gériatrie et Psychologie Neuropsychiatrie du Viellissement. https://doi.org/10.1684/pnv.2018.0728
400. Matamala, A. M., Hanna, M., Perrot, S., & Varrassi, G. (2022). Avoid Postoperative Pain To Prevent Its Chronification: A Narrative Review. Cureus. https://doi.org/10.7759/cureus.22243
401. Matheson, E. M., Brown, B. D., & DeCastro, A. O. (2024). Treatment of Chronic Insomnia in Adults.. PubMed.
402. Mauri, M., & Ramacciotti, D. (2006). Sintomi Psichici e Somatici dei Disturbi dell'Umore: razionali di terapia. Giornale italiano di psicopatologia/Journal of psychopathology/Italian journal of psychopathology.
403. Mayer, G. (2008). Excessive somnolence disorders. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511545085.007
404. McCann, J. C. (1949). Premedication in Anesthesia. New England Journal of Medicine. https://doi.org/10.1056/nejm194901062400104
405. McCrae, C. S., Ross, A., Stripling, A. M., & Dautovich, N. D. (2007). Eszopiclone for late-life insomnia.. PubMed.
406. McCurry, S. M., Logsdon, R. G., & Teri, L. (1996). Behavioral Treatment of Sleep Disturbance in Elderly Dementia Caregivers. Clinical Gerontologist. https://doi.org/10.1300/j018v17n02_04
407. McEwen, B. S. (1998). Stress, Adaptation, and Disease: Allostasis and Allostatic Load. Annals of the New York Academy of Sciences. https://doi.org/10.1111/j.1749-6632.1998.tb09546.x
408. McGorry, P. D., Purcell, R., Goldstone, S., & Amminger, G. P. (2011). Age of onset and timing of treatment for mental and substance use disorders: implications for preventive intervention strategies and models of care. Current Opinion in Psychiatry. https://doi.org/10.1097/yco.0b013e3283477a09
409. McKenzie, B., Walker, T., & Chin, C. (2018). Prevalence of Burnout in Bahamian Health Care Personnel. Journal of Occupational and Environmental Medicine. https://doi.org/10.1097/jom.0000000000001383
410. McNamara, P., Durso, R., & Auerbach, S. (2002). Dopaminergic syndromes of sleep, mood and mentation: Evidence from Parkinson's disease and related disorders. Sleep and Hypnosis.
411. Medina-Chávez, J. H., Fuentes-Alexandro, S., Gil-Palafox, I. B., Adame-Galván, L., Solís-Lam, F., Sánchez-Herrera, L. Y., & Narváez, F. S. (2014). [Clinical practice guideline. Diagnosis and treatment of insomnia in the elderly].. PubMed.
412. Medina-Chávez, J. H., Fuentes-Alexandro, S., Gil-Palafox, I. B., Adame-Galván, L., Solís-Lam, F., Sánchez-Herrera, L. Y., & Narváez, F. S. (2014). Diagnóstico y tratamiento del insomnio en el adulto mayor.
413. Meena, D., Chand, S., & Kumar, D. (2019). A Review Article on Selective Serotonin Reuptake Inhibitors (SSRIS). Asian Journal of Pharmaceutical Research and Development. https://doi.org/10.22270/ajprd.v7i6.592
414. Mehr, Z. P., Tabrizi, Z. M., Tajabadi, A., Saghi, Z., & Ghalenovi, S. (2019). Transient Loss of Consciousness; Syncope or Seizure: A Case Report. The Neuroscience Journal of Shefaye Khatam. https://doi.org/10.29252/shefa.7.4.71
415. Meyer, J. S., & Hamel, A. F. (2014). Models of Stress in Nonhuman Primates and Their Relevance for Human Psychopathology and Endocrine Dysfunction. ILAR Journal. https://doi.org/10.1093/ilar/ilu023
416. Meza-Ruiz, W., & Zúñiga-Escobar, G. (2023). Hematoma cerebral intraparenquimatoso e intraventricular por cocaína: reporte de un caso. Revista chilena de neuro-psiquiatría. https://doi.org/10.4067/s0717-92272023000100064
417. Michael, A., & Andrews, S. C. (2002). Paroxetine-Induced Vaginal Anaesthesia. Pharmacopsychiatry. https://doi.org/10.1055/s-2002-33196
418. Michie, S. (2002). CAUSES AND MANAGEMENT OF STRESS AT WORK. Occupational and Environmental Medicine. https://doi.org/10.1136/oem.59.1.67
419. Mihăicuţă, Ş., Muntean, D., Krohn, D., Marc, M., Fira‐Mladinescu, O., & Tudorache, V. (2006). [Excessive diurnal somnolence--causes, mechanisms, therapeutical approach].. PubMed.
420. Miller, D. D. (2007). Sedation with Antipsychotics: Manage, Don't Accept Adverse 'Calming' Effect. Current psychiatry.
421. Miller, M. W., Marx, B. P., & Keane, T. M. (2010). Posttraumatic Stress Disorder. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0699
422. Milne, A. (2017). DEPRESSION AMONG OLDER RESIDENTS IN LONG-TERM CARE: AN ILL UNDERSTOOD AND UNDERTREATED PROBLEM. Innovation in Aging. https://doi.org/10.1093/geroni/igx004.1913
423. MINEI, S., Kainuma, M., Sakamoto, H., Tamaki, N., TOMORI, H., CHOLSONG, Y., Nakahara, Y., & FURUSSYO, N. (2019). Consideration of a New Category of Patients for Whom Ryokeijutsukanto is Effective at a Different Stage Then was Previously Reported. Kampo Medicine. https://doi.org/10.3937/kampomed.70.141
424. Mistraletti, G., Carloni, E., Cigada, M., Zambrelli, E., Taverna, M., Sabbatini, G., Umbrello, M., Elia, G., Destrebecq, A., & Iapichino, G. (2008). Sleep and delirium in the intensive care unit.. PubMed.
425. Mitchell, P. B., Goodwin, G. M., Johnson, G. F., & Hirschfeld, R. M. A. (2008). Diagnostic guidelines for bipolar depression: a probabilistic approach. Bipolar Disorders. https://doi.org/10.1111/j.1399-5618.2007.00559.x
426. Mitler, M. M., Erman, M. K., & Hajduković, R. (1993). 3. The Treatment of Excessive Somnolence With Stimulant Drugs. SLEEP. https://doi.org/10.1093/sleep/16.3.203
427. Molleman, P. W., Kesteren, J. V., Ubink-Bontekoe, C., Zoomer-Hendriks, M. P. D., & Wetzels, R. B. (2015). [Canopy-enclosed bed for dementia patients with behavioural problems].. PubMed.
428. Monotti, R. (1993). [Drug emergencies].. PubMed.
429. Montgomery, S. (2006). Guidelines in major depressive disorder, and their limitations. International Journal of Psychiatry in Clinical Practice. https://doi.org/10.1080/13651500600940492
430. Montgomery, S., Bebbington, P., Cowen, P. J., Deakin, J., Freeling, P., Hallström, C., Katona, C., King, D. S., Leonard, B., Levine, S., Phanjoo, A. L., Peet, M., Thompson, C. M., & Thompson, C. M. (1993). Guidelines for treating depressive illness with antidepressants: A statement from the British Association for Psychopharmacology. Journal of Psychopharmacology. https://doi.org/10.1177/0269881193007001041
431. Monti, J. M., & Pandi‐Perumal, S. R. (2014). Role of zolpidem in the management of primary and comorbid insomnia. https://doi.org/10.2217/fmeb2013.13.146
432. Moreau, J., Scherschlicht, R., Jenck, F., & Martin, J. R. (1995). Chronic mild stress-induced anhedonia model of depression. Behavioural Pharmacology. https://doi.org/10.1097/00008877-199511000-00003
433. Morris, D. M. (1988). Management of perinatal bereavement.. Archives of Disease in Childhood. https://doi.org/10.1136/adc.63.7.870
434. Moukaddam, N., Cavazos, E., Nazario, M., Murtaza, S. T., & Shah, A. A. (2019). Depression and Its Impact on Adolescents. Psychiatric Annals. https://doi.org/10.3928/00485713-20190506-01
435. Moura, G. S., Neves, L. M. T., Giorelli, A. S., Florido, P., & Gomes, M. D. M. (2013). Transtornos do sono: visão geral Sleep disorders: overview.
436. Mude, G., Pise, S., Makade, K., Fating, R., & Wakodkar, S. (2021). Termiticidal Activity of Ethanolic and n- Hexane Leaf Extraction of Calotropis procera, Cannabis indica and Mentha longifolia Against a Higher Termite Microtomes obesi. Journal of Developing Drugs. https://doi.org/10.35248/2329-6631.21.10.206
437. Muntingh, A., Batelaan, N. M., & Balkom, A. J. V. (2019). [Relapse in anxiety disorders].. PubMed.
438. Muraosa, H., Suzuki, A., Noto, K., & Otani, K. (2020). Musical Hallucinations Induced by Conventional Doses of Paroxetine. American Journal of Case Reports. https://doi.org/10.12659/ajcr.926735
439. Mushthi, D., Chakraborty, R., Chaudhury, S., & Singh, A. (2025). Olanzapine-induced akathisia treated with clozapine. Industrial Psychiatry Journal. https://doi.org/10.4103/ipj.ipj_268_24
440. Musálek, M. (2011). Pathologisches Spielen: Impulskontrollstörung oder Sucht?. Suchttherapie. https://doi.org/10.1055/s-0031-1284655
441. Möller, H., Demyttenaere, K., Sacchetti, E., Rush, A. J., & Montgomery, S. (2003). Improving the chance of recovery from the short- and long-term consequences of depression. International Clinical Psychopharmacology. https://doi.org/10.1097/00004850-200307000-00004
442. Najib, J. (2012). Lisdexamfetamine in the treatment of adolescents and children with attention-deficit/hyperactivity disorder. Adolescent Health Medicine and Therapeutics. https://doi.org/10.2147/ahmt.s19815
443. Nakayama, H., Mihara, S., Sakuma, H., Kitamura, D., & Higuchi, S. (2014). SY08-3 * CO-MORBIDITY OF INTERNET ADDICTION. Alcohol and Alcoholism. https://doi.org/10.1093/alcalc/agu052.39
444. Narindra, S. K., & Musabiq, S. (2019). Combining Methods of CBT and Progressive Relaxation for Treating Primary Insomnia: A Case Study. https://doi.org/10.2991/iciap-18.2019.38
445. Nayak, R. D. (2015). Internet Addiction a Comparative Study between Undergraduate Students of India and Malaysia. International Journal of Indian Psychology. https://doi.org/10.25215/0204.088
446. Negro, A., Rocchietti-March, M., Fiorillo, M., & Martelletti, P. (2011). Chronic migraine: current concepts and ongoing treatments.. PubMed.
447. Neufeld, K. J., Needham, D. M., Oh, E. S., Wilson, L. M., Nikooie, R., Zhang, A., Koneru, M., Balagani, A., Singu, S., Aldabain, L., & Robinson, K. A. (2019). Antipsychotics for the Prevention and Treatment of Delirium. https://doi.org/10.23970/ahrqepccer219
448. Nielen, M. M. A. (2003). Where emotion meets cognition: studies on executive function in obsessive-compulsive disorder.
449. Nielsen, J. F., Klemar, B., Hansen, H., & Sinkjær, T. (1995). A new treatment of spasticity with repetitive magnetic stimulation in multiple sclerosis.. Journal of Neurology Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp.58.2.254-a
450. Nigg, J. T. (2003). Response Inhibition and Disruptive Behaviors. Annals of the New York Academy of Sciences. https://doi.org/10.1196/annals.1301.018
451. Nightall, C. (2018). Emotional reactions to serious diagnosis. Routledge eBooks. https://doi.org/10.4324/9780429474033-3
452. Nijdam, S. J. (1990). [Anxiety and depression caused by side effects of drugs].. PubMed.
453. Noble, F., & Roques, B. P. (2003). Inhibitors of Enkephalin Catabolism. Humana Press eBooks. https://doi.org/10.1007/978-1-59259-343-9_5
454. Nosek, M. A., & Howland, C. A. (1998). Abuse and Women with Disabilities.
455. Nunes, E. V., Deliyannides, D. A., Donovan, S. J., & McGrath, P. J. (1996). THE MANAGEMENT OF TREATMENT RESISTANCE IN DEPRESSED PATIENTS WITH SUBSTANCE USE DISORDERS. Psychiatric Clinics of North America. https://doi.org/10.1016/s0193-953x(05)70290-2
456. Nunes, J. T., Brigadeiro, D., Andrade, J., & Costa, A. P. D. (2017). Neuroleptic-induced Parkinsonism in Patient with Obsessive Compulsive Disorder: A Case Report. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2017.01.1063
457. Obradović, A., & Savić, M. M. (2017). Antidepressants: Myths, facts and perspectives. Arhiv za farmaciju. https://doi.org/10.5937/arhfarm1705291o
458. Ogbonna, C. I., & Lembke, A. (2017). Tapering Patients Off of Benzodiazepines.. PubMed.
459. Olesen, A. S., & Jensen, O. H. (2006). [Pain centers--why and when?].. Ugeskrift for Læger.
460. Olmedo, A., & Rolando, M. (2015). Informe psicológico pericial: situación de violencia intrafamiliar, “maltrato física, psicológica y sexual”, grado de afectación psicológico..
461. Olmos-López, A., Ibarra-Aguilar, J., Cornelio-Nieto, J. O., Ocaña-Hernández, L. A., Márquez-Amaya, M. A., Luna-López, N. A., Reséndiz-Aparicio, J. C., & Rodríguez‐Leyva, I. (2019). Clinical guideline: status epilepticus in children and adults. DELETED. https://doi.org/10.24875/rmn.m19000031
462. Onochie, E., & Verghese, J. (2025). A Case of Depersonalization-Derealization Disorder. BJPsych Open. https://doi.org/10.1192/bjo.2025.10752
463. Orme, S., & Harari, D. (2020). Bladder and bowels. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198746690.003.0060
464. Oshagh, M., Bahramnia, F., Aminsharifi, A., Fallahzadeh, M. H., & Ghodrati, P. (2014). Effects of maxillary expansion and placebo effect of appliances on nocturnal enuresis – preliminary results. Editor-in-Chief s Voice List of Authors is an Important Element in a Scientific Publication. https://doi.org/10.5173/ceju.2014.01.art11
465. Osterman, J. E., Erdos, B. Z., Oldham, M., & Ivkovic, A. (2010). Antidepressant Treatments in PTSD. Humana Press eBooks. https://doi.org/10.1007/978-1-60327-435-7_7
466. Otsuka, K., Kato, S., Abe, T., SUGIYAMA, H., Watanabe, Y., Kobayashi, T., & Okajima, Y. (2002). [Classification of long-term clinical course of 'atypical psychosis': a 20-year follow-up study at a medical school hospital].. PubMed.
467. Otten, R. I., Jansen, I., & Zeeman, M. (2019). [A vulnerable elderly man with prednisone-induced delirium].. PubMed.
468. Outhoff, K. (2019). Depression in doctors: A bitter pill to swallow. South African Family Practice. https://doi.org/10.4102/safp.v61i1.5046
469. Ownby, R. L. (2006). Medication adherence and cognition. Medical, personal and economic factors influence level of adherence in older adults.. PubMed.
470. O’Brien, C. P. (2005). Benzodiazepine use, abuse, and dependence.. PubMed.
471. O’Connor, F. G., & Levine, B. D. (2015). Syncope in Athletes of Cardiac Origin. Current Sports Medicine Reports. https://doi.org/10.1097/01.csmr.0000465136.70746.5b
472. Padmos, R. C. (2009). Inflammatory Monocytes in Bipolar Disorder and Related Endocrine Autoimmune Diseases.
473. Pal, H., Kumar, R., Bhushan, S., & Berry, N. (2005). Psychiatric co-morbidity associated with pheniramine abuse and dependence. Indian Journal of Psychiatry. https://doi.org/10.4103/0019-5545.46079
474. Pallesen, S., Olsen, O. K., Eide, E. M., Nortvedt, B., Grønli, J., Larøi, F., Nordmo, M., & Glomlien, F. E. (2018). Sleep deprivation and hallucinations. A qualitative study of military personnel. Military Psychology. https://doi.org/10.1080/08995605.2018.1478561
475. Palmirotta, C., Turi, G., Tagliente, S., Pansini, M., Trane, S. D., & Lagravinese, G. (2024). The Effects of Intensive Rehabilitation Combined with Thiamine Treatment on Cognitive Recovery in a Case of Non-Alcoholic Wernicke–Korsakoff Syndrome. Neurology International. https://doi.org/10.3390/neurolint16010018
476. Pan, Z., Grovu, R. C., Danielle, S., Carmona, N. E., Subramaniapillai, M., Shekotikhina, M., Rong, C., Lee, Y., & McIntyre, R. S. (2018). Pharmacological Treatment of Cognitive Symptoms in Major Depressive Disorder. CNS & Neurological Disorders - Drug Targets. https://doi.org/10.2174/1871527316666170919115100
477. Panconesi, A., Pl, D. B., Curradi, C., Franchi, G., Anselmi, B., & Andreini, R. (1991). [Headache caused by analgesic and/or ergotamine abuse].. PubMed.
478. Pannill, F. C. (1987). Urinary Incontinence1. Journal of the American Geriatrics Society. https://doi.org/10.1111/j.1532-5415.1987.tb02342.x
479. Paraschakis, A., & Konstantinidou, D. (2012). P-664 - Stalking of psychiatrists by their patients: an unsettling reality. European Psychiatry. https://doi.org/10.1016/s0924-9338(12)74831-9
480. Park, G., & Shelly, M. P. (2010). Sedation and analgesia in the critically ill. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199204854.003.1707
481. Parmet, S. (2003). Insomnia. JAMA. https://doi.org/10.1001/jama.289.19.2466
482. Parmet, S., Burke, A. E., & Glass, R. M. (2006). Insomnia. JAMA. https://doi.org/10.1001/jama.295.24.2952
483. Parmet, S., Lynm, C., & Glass, R. M. (2003). Insomnia. JAMA. https://doi.org/10.1001/jama.289.19.2602
484. Patti, L., & Gupta, M. (2019). Change In Mental Status. StatPearls.
485. Paulin, L. F. R. D. S., Reis, E. F. D., & Rodrigues, E. P. (2008). Síndrome de descontinuação dos antidepressivos.
486. Peacey, J., Miller, H., Huthwaite, M., & Romans, S. (2011). Sleep Medication in Acute Psychiatric Illness. The Journal of Nervous and Mental Disease. https://doi.org/10.1097/nmd.0b013e31823e6552
487. Pechnick, R. N., Cunningham, K. A., & Danovitch, I. (2014). Hallucinogen-Related Disorders. American Psychiatric Publishing eBooks. https://doi.org/10.1176/appi.books.9781585625048.gg51
488. Pedley, T. A., & Guilleminault, C. (1977). Episodic nocturnal wanderings responsive to anticonvulsant drug therapy. Annals of Neurology. https://doi.org/10.1002/ana.410020105
489. Peitl, M. V., Prološčić, J., Zelić, S. B., Skarpa-Usmiani, I., & Peitl, V. (2011). Symptoms of agitated depression and/or akathisia.. PubMed.
490. Peniston, J. H. (2012). A Review of Pharmacotherapy for Chronic Low Back Pain with Considerations for Sports Medicine. The Physician and Sportsmedicine. https://doi.org/10.3810/psm.2012.11.1985
491. Perera-Diltz, D. (2015). Cannabis Use Disorder. https://doi.org/10.63134/refd7106
492. Pergolizzi, J. V., Taylor, R. J., LeQuang, J. A., Gould, E. M., & Raffa, R. B. (2019). Treating Insomnia in Older Adult Patients: Limiting Benzodiazepine Use. Pharmacology &amp Pharmacy. https://doi.org/10.4236/pp.2019.103010
493. Perłowski, J., Miśkiewicz, M., Ptak, J., Noga, R., Teska, V., Marcinkowska, J., Herc, A., Koczkodon, K., Sawczuk, M., & Krompiewski, M. (2024). Recreational ketamine use and its impact on health. Journal of Education Health and Sport. https://doi.org/10.12775/jehs.2024.68.55185
494. Petruševičienė, D., & Kriščiūnas, A. (2003). [Occupational therapy for patients after stroke].. PubMed.
495. Piwuna, C. G., Makput, D. M., & Wakil, M. A. (2015). Persistent delusional disorder in a 32 year old male. Highland Medical Research Journal.
496. Piątek, A., Koziarska-Rościszewska, M., & Zawilska, J. B. (2015). Rekreacyjne używanie leków dostępnych w odręcznej sprzedaży: odurzanie i doping mózgu. Alcoholism and Drug Addiction. https://doi.org/10.1016/j.alkona.2015.03.001
497. Plaut, M., & Friedman, S. B. (1982). Stress, Coping Behavior and Resistance to Disease. Psychotherapy and Psychosomatics. https://doi.org/10.1159/000287635
498. Pogatzki‐Zahn, E., Marziniak, M., Schneider, G., Luger, T. A., & Ständer, S. (2008). Chronic Pruritus: Targets, Mechanisms and Future Therapies. Drug News & Perspectives. https://doi.org/10.1358/dnp.2008.21.10.1314057
499. Porter, K. A., Porcari, C., Koch, E. I., Fons, C. E., & Spates, C. R. (2006). In vivo exposure treatment for agoraphobia.. The Behavior Analyst Today. https://doi.org/10.1037/h0100161
500. Pothmann, R. (2008). Kopfschmerzen bei Kindern – Diagnostik und Therapie unterschiedlicher Kopfschmerzformen. Notfall & Hausarztmedizin. https://doi.org/10.1055/s-0028-1098954
501. Powner, D. J., & Boccalandro, C. (2008). Adrenal insufficiency following traumatic brain injury in adults. Current Opinion in Critical Care. https://doi.org/10.1097/mcc.0b013e3282f57528
502. Pozzoli, S., Altamura, A. C., & Bosi, M. (2006). Il trattamento a lungo termine della Depressione Unipolare: focus sulla terapia con Venlafaxina RP. Giornale italiano di psicopatologia/Journal of psychopathology/Italian journal of psychopathology.
503. Prajapati, B., Agarwal, A., Garg, D., Garg, A., Pandit, A., Radhakrishnan, D. M., & Srivastava, A. (2024). Delayed post-hypoxic parkinsonism with leukoencephalopathy associated with carbon monoxide poisoning. Annals of Movement Disorders. https://doi.org/10.4103/aomd.aomd_37_24
504. Prasad, K., Prasad, M., Ramaratnam, S., & Marson, A. G. (2015). Status epilepticus. https://doi.org/10.1002/9781119067344.ch9
505. Prathima, P. R., Johnson, D. B., Suresh, R., Venkatnarayanan, R., & Ahammad, P. M. A. (2013). Acute and Subacute Toxicity study of Milnacipran Hydrochloride in Wistar rats by Oral Route. Research Journal of Pharmacology and Pharmacodynamics.
506. Praško, J., Raszka, M., & Pastucha, P. (2009). Dissociative Disorders - Clinical Manifestation and Management. European Psychiatry. https://doi.org/10.1016/s0924-9338(09)70376-1
507. Preiß, M., Rabl, U., Popper, V., Watzal, V., Treiber, M., Ivkic, D., Praschak-Rieder, N., Naderi‐Heiden, A., Fugger, G., Frey, R., Rujescu, D., & Bartova, L. (2023). Case report: Hyperactive delirium after a single dose of zolpidem administered additionally to psychopharmacotherapy including clozapine. Frontiers in Psychiatry. https://doi.org/10.3389/fpsyt.2023.1204009
508. Proczkowska‐Björklund, M., Gustafsson, P., & Svedin, C. G. (2010). Children’s play after anaesthesia and surgery: background factors and associations to behaviour during anaesthetic induction. Journal of Child Health Care. https://doi.org/10.1177/1367493509359225
509. Prommer, E. (2006). Prevalence and characterization of the insomnia syndrome in an outpatient oncology clinic. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2006.24.18_suppl.18612
510. Pugliese, M., Rossi, C., Guidotti, I., Gallo, C., Casa, E. D., Bertoncelli, N., Coccolini, E., & Ferrari, F. (2013). Preterm birth and developmental problems in infancy and preschool age Part II: cognitive, neuropsychological and behavioural outcomes. The Journal of Maternal-Fetal & Neonatal Medicine. https://doi.org/10.3109/14767058.2013.794205
511. Pujol, R., & Puel, J. (1999). Excitotoxicity, Synaptic Repair, and Functional Recovery in the Mammalian Cochlea: A Review of Recent Findings. Annals of the New York Academy of Sciences. https://doi.org/10.1111/j.1749-6632.1999.tb08646.x
512. Pylypenko, M., & Mykhaylov, B. (2021). JUSTIFICATION FOR THE COMBINED USE OF PROPOFOL AND DEXMEDETOMIDINE IN ELECTIVE PROCEDURAL SEDATION. Pain anesthesia and intensive care. https://doi.org/10.25284/2519-2078.3(96).2021.242135
513. Pyszora, N., Fahy, T., & Kopelman, M. D. (2014). Amnesia for violent offenses: factors underlying memory loss and recovery.. PubMed.
514. Pétursson, H. (1994). The benzodiazepine withdrawal syndrome. Addiction. https://doi.org/10.1111/j.1360-0443.1994.tb03743.x
515. Rada, F. M., & Lucas-Taracena, M. T. D. (2006). [Swallowing phobia: symptoms, diagnosis and treatment].. PubMed.
516. Rajesh, M., & Kumar, C. P. G. (2014). Influence of interactional relationship on stress among women executives in software company in Chennai. EXCEL International Journal of Multidisciplinary Management Studies.
517. Ramachandran, P., Raghavan, V., Cherubal, A., & John, S. (2020). Comparison of cost-effectiveness of long-acting depot injection antipsychotics and oral antipsychotics in patients with schizophrenia in a rural community in South India. Indian Journal of Psychiatry. https://doi.org/10.4103/psychiatry.indianjpsychiatry_670_19
518. Rani, S., & Saini, D. S. (2015). Organizational Stress in Relation to Job Satisfaction and General Health of Professional Women. International journal of education and management studies.
519. Rao, T. S., & Kumar, M. A. (2008). Agenda for specialty section in addiction medicine. Indian Journal of Psychiatry. https://doi.org/10.4103/0019-5545.44741
520. Rastegar, D. A., & Fingerhood, M. (2015). Hallucinogens and Dissociatives. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190214647.003.0009
521. Rees, C. S., & Anderso, R. (2013). New Approaches to the Psychological Treatment of Obsessive- Compulsive Disorder in Adults. InTech eBooks. https://doi.org/10.5772/53070
522. Reeves, R. R., & Kamal, A. H. (2019). Complicated Withdrawal Phenomena During Benzodiazepine Cessation in Older Adults. Journal of Osteopathic Medicine. https://doi.org/10.7556/jaoa.2019.055
523. Regnard, C., Kindlen, M., & Nichol, T. (2018). Helping the anxious person. CRC Press eBooks. https://doi.org/10.1201/9781315376363-29
524. Reif, S. J., & Layon, A. J. (2020). A pilot volunteer reader programme decreases delirium days in critically ill, adult ICU patients. BMJ Open Quality. https://doi.org/10.1136/bmjoq-2019-000761
525. Reilly, T. E., & Waterhouse, J. (2008). Time-zone travel, jet lag, and sleep disturbances. CRC Press eBooks. https://doi.org/10.3109/9780203091715-44
526. Reinares, M., Martínez‐Arán, A., & Vieta, E. (2019). Psychoeducation for Patients and Family Members. Cambridge University Press eBooks. https://doi.org/10.1017/9781108589802.004
527. Reinhold, J. A., Mandos, L. A., Lohoff, F. W., & Rickels, K. (2012). Evidence for the use of vilazodone in the treatment of major depressive disorder. Expert Opinion on Pharmacotherapy. https://doi.org/10.1517/14656566.2012.721776
528. Renault, P. F., Hoofnagle, J. H., Park, Y., Mullen, K. D., Peters, M. G., Jones, D. B., Rustgi, V. K., & Jones, E. A. (1987). Psychiatric Complications of Long-term Interferon Alfa Therapy. Archives of Internal Medicine. https://doi.org/10.1001/archinte.1987.00370090055011
529. Reynolds, A. C., & Adams, R. (2019). Treatment of sleep disturbance in older adults. Journal of Pharmacy Practice and Research. https://doi.org/10.1002/jppr.1565
530. Riaz, A., Shahid, Q., Yousaf, H. M., Gul, U., Shah, S. S., Hidayat, A., Hamid, T., Rahman, A. U., Usman, M., Khan, M. K., Muhtiar, R., & Khalid, B. (2024). Mirtazapine in Primary Insomnia: Case report and Literature review. World Journal of Advanced Research and Reviews. https://doi.org/10.30574/wjarr.2024.23.1.2213
531. Riaz, Y., & Sergi, C. (2021). Feeding Disability In Children.
532. Richards, J. H. (2025). Methamphetamine Washout Syndrome: More than Just Catecholamine Depletion?. Medical Research Archives. https://doi.org/10.18103/mra.v13i4.6514
533. Robertson, O. D., Coronado, N. G., Sethi, R., Berk, M., & Dodd, S. (2019). Putative neuroprotective pharmacotherapies to target the staged progression of mental illness. Early Intervention in Psychiatry. https://doi.org/10.1111/eip.12775
534. Rodrigo, M. L., Monge, M. P., Fominaya, M. P., Oliver, A. O., Guerra, M. T., Montero, C. G., & Font, V. R. (2022). Two of us live in this body. European Psychiatry. https://doi.org/10.1192/j.eurpsy.2022.2256
535. Rodriguez, P. M. (2019). 1053 Narcolepsy in Tourette syndrome. SLEEP. https://doi.org/10.1093/sleep/zsz069.1050
536. Rodríguez, E. O., Esquivel, P. S., & Triana, I. M. (2024). Un panorama actualizado de la dispepsia. Revista médica de Panamá. https://doi.org/10.37980/im.journal.rmdp.20242296
537. Rollin‐Sillaire, A., Delbeuck, X., Pollet, M., Mackowiak, M., Lenfant, P., Noël, M., Façon, T., Leleu, X., Pasquier, F., & Rhun, É. L. (2013). Memory loss during lenalidomide treatment: a report on two cases. BMC Pharmacology and Toxicology. https://doi.org/10.1186/2050-6511-14-41
538. Ronad, S. V., Patail, C. S., Gondbal, S. H., TC, K., Ronad, M., Pankaja, T., Badesgol, R., & Singhal, P. K. J. (2019). Professionals in metro cities suffer from anxiety disorder. Nursing & Care Open Access Journal. https://doi.org/10.15406/ncoaj.2019.06.00198
539. Rosa, E. F., & Rustiaty, N. (2018). Affective Disorders in The Elderly: The Risk of Sleep Disorders. International Journal of Public Health Science (IJPHS). https://doi.org/10.11591/ijphs.v7i1.9960
540. Rosenbaum, J. F., & Zajecka, J. (1997). Clinical management of antidepressant discontinuation.. PubMed.
541. Ross, E. J., Cassisi, J. E., & Lofland, K. R. (2019). Chronic Back Pain. Routledge eBooks. https://doi.org/10.4324/9781351164047-9
542. Rotenberg, V. S. (2003). Sleep deprivation in depression: An integrative approach. International Journal of Psychiatry in Clinical Practice. https://doi.org/10.1080/13651500310001013
543. Roth, T., Krystal, A. D., & Lieberman, J. A. (2007). Long-term issues in the treatment of sleep disorders.. CNS Spectrums.
544. Rowe, P. C., Underhill, R., Friedman, K. J., Gurwitt, A., Medow, M. S., Schwartz, M., Speight, N., Stewart, J. M., Vallings, R., & Rowe, K. S. (2017). Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Diagnosis and Management in Young People: A Primer. Frontiers in Pediatrics. https://doi.org/10.3389/fped.2017.00121
545. Rubiales, Á. S., Duarte, F. J. B., & Valle, M. L. D. (2015). Es necesario precisar el concepto de sedación. Cuadernos de bioética/Cuadernos de bioética.
546. Rucci, J. M., & Feinstein, R. E. (2014). Neurocognitive Disorders and Mental Disorders Due to Another Medical Condition. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199326075.003.0005
547. Saad, S., Shaboob, E., & Alwakeel, Z. (2020). Anesthetic Considerations in Epilepsy. Benha Journal of Applied Sciences. https://doi.org/10.21608/bjas.2020.135407
548. Sakalauskaitë-Juodeikienë, E., & Masaitienė, R. (2018). Naujas nemigos apibrėžimas, etiopatogenezė, diagnostikos ir gydymo algoritmas. Neurologijos seminarai. https://doi.org/10.29014/ns.2018.20
549. Salama, A. Z., Dabash, M. R., Elayan, A., Saadeh, S., & Ikhmayyes, I. (2024). Dissociative Trance Led to a Catastrophe: A Case Report. Cureus. https://doi.org/10.7759/cureus.76458
550. Saletu‐Zyhlarz, G., Anderer, P., & Saletu, B. (2013). [Sleep disorders in psychiatry and their treatment].. PubMed.
551. Salkind, A. R. (1997). Coma From Long-term Overingestion of Isoniazid. Archives of Internal Medicine. https://doi.org/10.1001/archinte.1997.00440420156017
552. Sanchis‐Segura, C., & Spanagel, R. (2006). REVIEW: Behavioural assessment of drug reinforcement and addictive features in rodents: an overview. Addiction Biology. https://doi.org/10.1111/j.1369-1600.2006.00012.x
553. Sanders, P. T., Cysyk, B. J., & Bare, M. A. (1996). Safety in Long-Term EEG/Video Monitoring. Journal of Neuroscience Nursing. https://doi.org/10.1097/01376517-199610000-00004
554. Sandi, C. (2013). Stress and cognition. Wiley Interdisciplinary Reviews Cognitive Science. https://doi.org/10.1002/wcs.1222
555. Sandoval-Munoz, C. P., & Haidar, Z. S. (2021). Neuro-Muscular Dentistry: the “diamond” concept of electro-stimulation potential for stomato-gnathic and oro-dental conditions. Head & Face Medicine. https://doi.org/10.1186/s13005-021-00257-3
556. Santos, M. G. (2023). Adult ADHD: 6 studies of pharmacologic interventions. Current psychiatry. https://doi.org/10.12788/cp.0344
557. Sanxhaku, D., Kodra, V., Alikaj, V., Allkoja, B., & Zenelaj, B. (2017). Child obsessive-compulsive disorder presenting with catatonic-like features: Case presentation. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2017.01.461
558. Sarkar, S., Bhatia, G., & Dhawan, A. (2023). Clinical Practice Guidelines for Assessment and Management of Patients with Substance Intoxication Presenting to the Emergency Department. Indian Journal of Psychiatry. https://doi.org/10.4103/indianjpsychiatry.indianjpsychiatry_490_22
559. Sayyah, M., Majzoob, S., & Sayyah, M. (2013). Metabolic and toxicological considerations for obsessive–compulsive disorder drug therapy. Expert Opinion on Drug Metabolism & Toxicology. https://doi.org/10.1517/17425255.2013.783011
560. Schenck, C. H. (2003). Assessment and Management of Insomnia. JAMA. https://doi.org/10.1001/jama.289.19.2475
561. Schmauß, M., & Pajonk, F. (2015). Agitation und Aggression in der Psychiatrie. Fortschritte der Neurologie · Psychiatrie. https://doi.org/10.1055/s-0041-111184
562. Schutte, M., Mathias, B., & Hopf, G. (1988). [Adverse effects of antihistaminics].. PubMed.
563. Schweitzer, J. B. (2010). Attention‐Deficit/Hyperactivity Disorder. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0096
564. Scott, S., & Palmer, M. (2020). Conduct disorders and antisocial personality disorder in childhood and adolescence. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198713005.003.0124
565. Sejdić, E., Malandraki, G. A., & Coyle, J. L. (2018). Computational Deglutition: Using Signal- and Image-Processing Methods to Understand Swallowing and Associated Disorders [Life Sciences]. IEEE Signal Processing Magazine. https://doi.org/10.1109/msp.2018.2875863
566. Seligman, L. D., Swedish, E. F., & Ollendick, T. H. (2014). Anxiety Disorders in Children. https://doi.org/10.1002/9781394259359.ch7
567. Sengupta, R., Roy, S., & Bhattacharya, M. (2019). STUDY OF GENE-ENVIRONMENT CAUSES OF MAJOR DEPRESSIVE DISORDER TO STATISTICALLY DEFINE THE MOST COMMON CAUSE BEHIND IT.. International Journal of Advanced Research. https://doi.org/10.21474/ijar01/8804
568. Serageldin, M., Hikmet, W., & Alani, S. (2019). Insomnia is a Prodromal Symptom for Psychosis. Journal of the Bahrain Medical Society. https://doi.org/10.26715/jbms.31_31012019
569. Shah, R. R. (2005). Mechanistic basis of adverse drugreactions: the perils of inappropriate dose schedules. Expert Opinion on Drug Safety. https://doi.org/10.1517/14740338.4.1.103
570. Shams, J., Rahmani, B., Asefi, F., & Daneshfar, S. (2010). CATATONIA DEVELOPMENT IN A SCHIZOAFFECTIVE PATIENT FOLLOWING ELECTROCONVULSIVE THERAPY: CASE REPORT.
571. Sharma, B. (2017). Antidepressants: Mechanism of Action, Toxicity and Possible Amelioration. Journal of Applied Biotechnology & Bioengineering. https://doi.org/10.15406/jabb.2017.03.00082
572. Sharp, L. K., & Lipsky, M. S. (2002). Screening for depression across the lifespan: a review of measures for use in primary care settings.. PubMed.
573. Sheets, E. S., & Brosse, A. L. (2010). Major Depressive Disorder. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0522
574. SheikhBahaei, S., Farhan, M., & Maguire, G. A. (2022). Improvement of stuttering after administration of methylphenidate - a case report. Personalized Medicine in Psychiatry. https://doi.org/10.1016/j.pmip.2022.100092
575. Sherman, D. S. (1988). Psychoactive Drug Misuse in Long-Term Care: Some Contributing Factors. Journal of Pharmacy Practice. https://doi.org/10.1177/089719008800100307
576. Shih, T., & Bazil, C. W. (2005). Treatment of Generalized Convulsive Status Epilepticus. Humana Press eBooks. https://doi.org/10.1385/1-59259-945-1:265
577. Shinohara, R. C., Inoue, K., Takayanagi, S., Furutaka, Y., Yamazaki, H., & Watanabe, S. (2025). Successful treatment with lithium carbonate for periodic psychosis of adolescence. Psychiatry and Clinical Neurosciences Reports. https://doi.org/10.1002/pcn5.70133
578. Shirley, E. A., Hudspeth, L. J., & Maynard, J. R. (2018). Managing Sports-related Concussions From Time of Injury Through Return to Play. Journal of the American Academy of Orthopaedic Surgeons. https://doi.org/10.5435/jaaos-d-16-00684
579. Silva, L. I. F. D., Souza, L. M., Gonzales, M. F., & Jurado, S. R. (2015). SLEEP DISORDERS IN CHILDHOOD. Simpósio Internacional de Neurociências da Grande Dourados.
580. Singh, R., Chakravarty, K., Baishya, J., Goyal, M., & Kharbanda, P. (2020). Management of Refractory Epilepsy. International Journal of Epilepsy. https://doi.org/10.1055/s-0040-1712777
581. Sireesha, S. R., Boorla, V., & Bhogaraju, A. (2013). Prolonged delirium secondary to hypoxic ischemic encephalopathy following complete hanging. Archives of Mental Health. https://doi.org/10.4103/2589-9171.227665
582. Skalski, M., & Szczęsna, M. (2019). Modern standards for pharmacological treatment of insomnia. Pediatria i Medycyna Rodzinna. https://doi.org/10.15557/pimr.2019.0062
583. Smid, G. E., Lenferink, L. I. M., Keijser, J. D., & Boelen, P. A. (2017). Ambiguous loss in relatives of missing or disappeared persons.
584. Smith, H. S., & Meek, P. D. (2012). Milnacipran Hydrochloride in the Treatment of Fibromyalgia Syndrome: Safety, Efficacy and Tolerability. Clinical Medicine Insights Therapeutics. https://doi.org/10.4137/cmt.s2247
585. Smith, P. J., & Blumenthal, J. A. (2015). Exercise and Physical Activity in the Prevention and Treatment of Depression. Routledge eBooks. https://doi.org/10.4324/9780203132678.ch8
586. Snaith, P. (1994). Anxiety Control Training. Advances in Psychiatric Treatment. https://doi.org/10.1192/apt.1.2.57
587. Soares, E. B., Pires, J. B., Menezes, M. D. A., Santana, S. K. S. D., & Fraga, J. (2010). Fonoaudiologia X ronco/apneia do sono. Revista CEFAC. https://doi.org/10.1590/s1516-18462010000200019
588. Sriramoju, M., Keerthi, V. P., Alumdri, D. B., & Akula, S. (2014). Evaluation of antidepressant activity of ethanolic and aqueous extract of Solanum tuberosum peel. Journal of Comprehensive Pharmacy. https://doi.org/10.37483/jcp.2014.1503
589. Stearns, M., McCrae, C. S., Curtis, A., Nair, N., Hayse, B., Nadorff, D., & Wilkerson, A. K. (2024). Adolescent sleep mediates maternal depressive problems and parenting behaviors: daughter and son differences in a majority Black and Hispanic sample. Journal of Clinical Sleep Medicine. https://doi.org/10.5664/jcsm.10996
590. Steefan, J. M., Siddesha, G., & Naveen, A. (2023). Adverse Effects of Antipsychotic Drugs - A Review. International Journal of Research and Review. https://doi.org/10.52403/ijrr.20230916
591. Stewart, J. (2003). Stress and Relapse to Drug Seeking: Studies in Laboratory Animals Shed Light on Mechanisms and Sources of Long‐Term Vulnerability. American Journal on Addictions. https://doi.org/10.1111/j.1521-0391.2003.tb00535.x
592. Stewart, S. M. (2013). Depression. The Encyclopedia of Cross‐Cultural Psychology. https://doi.org/10.1002/9781118339893.wbeccp158
593. Stratakis, C. A., Gold, P. W., & Chrousos, G. P. (1995). Neuroendocrinology of Stress: Implications for Growth and Development. Hormone Research. https://doi.org/10.1159/000184269
594. Streufert, S., Satish, U., Pogash, R., Gingrich, D., Landis, J. R., Lonardi, L., Miller, J., Severs, W. B., & Roache, J. D. (1996). Effects of Alprazolam on Complex Human Functioning1. Journal of Applied Social Psychology. https://doi.org/10.1111/j.1559-1816.1996.tb00105.x
595. Stringaris, A., & Krieger, F. (2013). Bipolar disorder and disruptive mood dysregulation in children and adolescents: assessment, diagnosis and treatment. Evidence-Based Mental Health. https://doi.org/10.1136/eb-2013-101400
596. Stéru, L., Rouillon, F., & Wood, S. K. (1996). Methodological approaches to the long-term study of antidepressants. European Psychiatry. https://doi.org/10.1016/0924-9338(96)85173-x
597. Subodh, N. B., Jayarajan, D., Chand, P., Benegal, V., & Murthy, P. (2011). Lamotrigine-Induced Manic Switch. The Primary Care Companion For CNS Disorders. https://doi.org/10.4088/pcc.10l01034
598. Suh, S.-H. (2005). Eastside Psychiatric Services.
599. Sung, H. C., & Chang, A. B. (2010). The effectiveness of preferred or familiar music listening on behavioural and psychological symptoms of institutionalised older adults with dementia: a systematic review. JBI Library of Systematic Reviews. https://doi.org/10.11124/jbisrir-2010-726
600. Sung, H. C., & Chang, A. B. (2010). The effectiveness of preferred or familiar music listening on behavioural and psychological symptoms of institutionalised older adults with dementia: a systematic review. The JBI Database of Systematic Reviews and Implementation Reports. https://doi.org/10.11124/01938924-201008341-00020
601. Susanti, N., Hartiyah, & Kuntowato, D. (2015). HUBUNGAN BERDIRI LAMA DENGAN KELUHAN NYERI PUNGGUNG BAWAH MIOGENIK PADA PEKERJA KASIR DI SURAKARTA. Pena Medika Jurnal Kesehatan. https://doi.org/10.3194/pmjk.v5i1.346
602. Sussman, S. (2025). Vulnerability to addictive behaviors: the Associational Memory‐Appetitive Systems Relations Model. World Psychiatry. https://doi.org/10.1002/wps.21283
603. Sussman, S., & Ames, S. L. (2008). Concepts of Cessation. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511500039.016
604. Swann, A. C. (2012). Impulsivity and Affective Regulation. Oxford University Press eBooks. https://doi.org/10.1093/oxfordhb/9780195389715.013.0084
605. Swegle, J., & Logemann, C. D. (2006). Management of common opioid-induced adverse effects.. PubMed.
606. Szkodny, L. E., Jacobson, N. C., Llera, S. J., & Newman, M. G. (2014). Generalized Anxiety Disorder. American Psychiatric Publishing eBooks. https://doi.org/10.1176/appi.books.9781585625048.gg19
607. Sánchez, A. C. (2022). A Nightmare’s Lullaby: Exploring the concept and relevance of oneiroid cyclic psychosis through a clinical case and review. European Psychiatry. https://doi.org/10.1192/j.eurpsy.2022.1827
608. Söderpalm, B. (2002). Anticonvulsants: aspects of their mechanisms of action. European Journal of Pain. https://doi.org/10.1053/eujp.2001.0315
609. Tacn, A. (2012). PTSD in the Context of Malignant Disease. InTech eBooks. https://doi.org/10.5772/27424
610. Takada, S. (2020). Prevention and diagnosis of neuropathy during dental treatment. Japanese Journal of Oral & Maxillofacial Surgery. https://doi.org/10.5794/jjoms.66.530
611. Takahashi, A., & Franklin, J. (1996). Alcohol Abuse. Pediatrics in Review. https://doi.org/10.1542/pir.17-2-39
612. Takahashi, A., & Franklin, J. (1996). Alcohol Abuse. Pediatrics in Review. https://doi.org/10.1542/pir.17.2.39
613. Tan, B. L. W., & Gudi, A. (2021). A rare case: Mania associated with pazopanib. Proceedings of Singapore Healthcare. https://doi.org/10.1177/20101058211023778
614. Tanaka, M., Tajima, S., Mizuno, K., Ishii, A., Konishi, Y., Miike, T., & Watanabe, Y. (2015). Frontier studies on fatigue, autonomic nerve dysfunction, and sleep-rhythm disorder. The Journal of Physiological Sciences. https://doi.org/10.1007/s12576-015-0399-y
615. Tedyanto, E. H., Adnyana, I. M. O., & Widyadharma, I. P. E. (2023). Tension-type Headache and Migraine as Manifestations of Chronic Post-Traumatic Headache. Cermin Dunia Kedokteran. https://doi.org/10.55175/cdk.v50i2.528
616. Teicher, M. H., Cohen, B. M., Baldessarini, R. J., & Cole, J. O. (1988). Severe daytime somnolence in patients treated with an MAOI. American Journal of Psychiatry. https://doi.org/10.1176/ajp.145.12.1552
617. Tepper, S. J. (2008). Preventive Pharmacologic Treatment of Migraine and Tension-Type Headache. https://doi.org/10.1093/oso/9780195366730.003.0012
618. Tepper, S. J. (2012). Advanced Interventions for Headache. Headache The Journal of Head and Face Pain. https://doi.org/10.1111/j.1526-4610.2012.02133.x
619. Terman, M., Lewy, A. J., Dijk, D., Boulos, Z., Eastman, C. I., & Campbell, S. S. (1995). Light Treatment for Sleep Disorders: Consensus Report. Journal of Biological Rhythms. https://doi.org/10.1177/074873049501000206
620. Thakur, A., Choudhary, D., Kumar, B., & Chaudhary, A. (2021). A Review on Post-traumatic Stress Disorder (PTSD): Symptoms, Therapies and Recent Case Studies. Current Molecular Pharmacology. https://doi.org/10.2174/1874467214666210525160944
621. Tharani, Z., Musaddique, A., & Qutb, S. H. (2023). Burnout and its impact on Nurses and Doctors. Journal of the Pakistan Medical Association. https://doi.org/10.47391/jpma.23-69
622. Tholen, A. J., Hoek, H. W., & Giel, R. (1987). The Classification and Assessment of Intellectual and Other Psychological Impairments in the Mentally Disabled. International Journal of Mental Health. https://doi.org/10.1080/00207411.1987.11449076
623. Thomas, P. (2003). Treatment options for acute mania. European Psychiatry. https://doi.org/10.1016/s0924-9338(03)80011-1
624. Thomas, P., Hazif‐Thomas, C., & Clément, J. (2008). [Loss of motivation in the elderly].. HAL (Le Centre pour la Communication Scientifique Directe).
625. Thompson, H. (2012). Screening, Assessment, and Intervention for Intimate Partner Violence in Integrated Care. Routledge eBooks. https://doi.org/10.4324/9780203825730-14
626. Tiglao, S. M., Meisenheimer, E. S., & Oh, R. (2021). Alcohol Withdrawal Syndrome: Outpatient Management.. American family physician.
627. Tito, E., Knapp, B., Bucca, A., & Espiridion, E. D. (2019). A Case Report of Schizoaffective Disorder with Pseudoseizures in a 42-year-old Male. Cureus. https://doi.org/10.7759/cureus.4835
628. Tobias, J., & Gopalakrishnan, S. (2012). Premedication: Is clonidine the answer?. Saudi Journal of Anaesthesia. https://doi.org/10.4103/1658-354x.93041
629. Tollefson, G. D., Rampey, A. H., Potvin, J. H., Jenike, M. A., Rush, A. J., Dominguez, R. A., Koran, L. M., Shear, M. K., Goodman, W. K., & Genduso, L. A. (2022). A Multicenter Investigation of Fixed-Dose Fluoxetine in the Treatment of Obsessive-compulsive Disorder. Routledge eBooks. https://doi.org/10.4324/9780203822937-24
630. Tonks, A. (2003). Extracts from "Best Treatments": Treating generalised anxiety disorder * Commentary: Putting research into practice * Commentary: A patient's story of living with anxiety * Commentary: Information for patients receiving cognitive therapy. BMJ. https://doi.org/10.1136/bmj.326.7391.700
631. Toom, K., Braschinsky, M., Obermann, M., & Katsarava, Z. (2020). Secondary headache attributed to exposure to or overuse of a substance. Cephalalgia. https://doi.org/10.1177/0333102420942238
632. Torres, C. F., & Zubizarreta‐Macho, Á. (2022). Mandibular advancement appliances to treat apnea: an update of the most used currently. A systematic review and meta-analysis. https://doi.org/10.37766/inplasy2022.11.0034
633. Touloumis, C. (2021). Treatment resistant depression: Challenges and therapeutic choices. Psychiatriki. https://doi.org/10.22365/jpsych.2021.047
634. Tran, K., & Ford, C. (2020). Lurasidone Hydrochloride for Bipolar Disorder: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines [Internet].
635. Tran, K., & McCormack, S. (2020). Ketamine for Chronic Non-Cancer Pain: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines [Internet].
636. Travers, C., MacAndrew, M., Hines, S., O’Reilly, M., Fielding, E., Beattie, E., & Brooks, D. (2015). The effectiveness of meaningful occupation interventions for people living with dementia in residential aged care: a systematic review protocol. The JBI Database of Systematic Reviews and Implementation Reports. https://doi.org/10.11124/01938924-201513040-00008
637. Travers, C., MacAndrew, M., Hines, S., O’Reilly, M., Fielding, E., Beattie, E., & Brooks, D. (2015). The effectiveness of meaningful occupation interventions for people living with dementia in residential aged care: a systematic review protocol. The JBI Database of Systematic Reviews and Implementation Reports. https://doi.org/10.11124/jbisrir-2015-2058
638. Treanor, M., & Roemer, L. (2010). Generalized Anxiety Disorder. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0379
639. Treiman, D. M. (1993). Generalized Convulsive Status Epilepticus in the Adult. Epilepsia. https://doi.org/10.1111/j.1528-1157.1993.tb05902.x
640. Trifu, S., Drăgoi, A. M., & Trifu, A. D. (2019). Evolutive Possibilities Of Acute And Transitory Psychotic Disorder. The European Proceedings of Social & Behavioural Sciences. https://doi.org/10.15405/epsbs.2019.11.84
641. Trivedi, K., Kataria, L., & Patel, D. (2020). A COMPARATIVE STUDY EVALUATING THE DEPRESSIVE SYMPTOMS AND FUNCTIONAL OUTCOME IN PATIENTS TREATED WITH SELECTIVE SEROTONIN REUPTAKE INHIBITORS V/S SEROTONIN–NOREPINEPHRINE REUPTAKE INHIBITORS AS ANTIDEPRESSANT AGENTS IN MAJOR DEPRESSIVE DISORDER.
642. Trosch, R., Comella, C. L., Caroff, S. N., Ondo, W. G., Shillington, A. C., LaChappelle, B., Hauser, R. A., Correll, C. U., & Friedman, J. H. (2023). Reliability of the Clinician’s Tardive Inventory (CTI). CNS Spectrums. https://doi.org/10.1017/s1092852923001347
643. Troupin, A. S., Bencze, K., & Prockop, L. D. (1988). Reflex Absence Epilepsy. Epilepsia. https://doi.org/10.1111/j.1528-1157.1988.tb05097.x
644. Tseng, Y., Wellman, S. E., & Ho, I. (2020). Sedative-Hypnotics: Addiction and Current Research Status. Journal of Food and Drug Analysis. https://doi.org/10.38212/2224-6614.3068
645. Turkia, M. (2024). The mechanism of action in a spontaneous resolution of chronic depression, anxiety, and burnout—a retrospective case study. https://doi.org/10.31234/osf.io/2439q
646. Tym, R., Beaumont, P. R., & Lioulios, T. (2009). Two persisting pathophysiological visual phenomena following psychological trauma and their elimination with rapid eye movements: A possible refinement of construct PTSD and its visual state marker.. Traumatology An International Journal. https://doi.org/10.1177/1534765609335521
647. Unknown (2024). Effectiveness of Cognitive Behavioral Therapy (CBT) Combined with Brief Hypnotherapy (BH) in the Treatment of Persistent Enuresis in Adolescence in an Institutional Setting, Literature Review and Case Study. Journal of Clinical Review & Case Reports. https://doi.org/10.33140/jcrc.09.05.01
648. Unknown (2024). MANAGEMENT OF PANIC DISORDER THROUGH AYURVEDA: A CASE REPORT. International Journal of Biology Pharmacy and Allied Sciences. https://doi.org/10.31032/ijbpas/2024/13.6.8119
649. Unknown (2024). Safe Deprescribing of Antidepressants. https://doi.org/10.1002/9781394291052.mdg002
650. Unknown (2024). Safe Deprescribing of Benzodiazepines and Z‐drugs. https://doi.org/10.1002/9781394291052.mdg003
651. Uppalapati, M., Strohl, K. P., & Sibilia, R. (2021). 854 Sexsomnia in a Divorce Proceeding and its Custody Implications. SLEEP. https://doi.org/10.1093/sleep/zsab072.851
652. Valente, S. M. (2015). Evaluating and Managing Insomnia: Non-pharmacological Treatments. Journal of Sleep Disorders & Therapy. https://doi.org/10.4172/2167-0277.1000189
653. Vecchiet, J., Vecchiet, L., Rg, B., & Giamberardino, M. (1999). Muscle Pain from Physical Exercise. Journal of Musculoskeletal Pain. https://doi.org/10.1300/j094v07n01_05
654. Vendruscolo, L. F., & Koob, G. F. (2019). Alcohol Dependence Conceptualized as a Stress Disorder. https://doi.org/10.1093/oxfordhb/9780190681777.013.9
655. Verhagen, E. H., Hesselmann, G. M., Besse, T. C., & Graeff, A. D. (2005). [Palliative sedation].. PubMed.
656. Verhoeff, M. C., Baat, C. D., Ahlberg, J., Manfredini, D., Winocur, E., Zweers, P. G., Rozema, F. R., Vissink, A., & Lobbezoo, F. (2020). Medications and addictive substances potentially inducing or attenuating sleep bruxism and/or awake bruxism. Journal of Oral Rehabilitation. https://doi.org/10.1111/joor.13061
657. Verma, R., Kumar, N., & Kuppili, P. P. (2018). Repetitive Transcranial Magnetic Stimulation. The Primary Care Companion For CNS Disorders. https://doi.org/10.4088/pcc.17l02199
658. Verster, J. C., Volkerts, E. R., Spence, D. W., Alford, C., & Pandi‐Perumal, S. R. (2007). Effects of Sleep Medications on Cognition, Psychomotor Skills, Memory and Driving Performance in the Elderly. Current Psychiatry Reviews. https://doi.org/10.2174/157340007782408860
659. Viljoen, M. F. (2015). Sleep tips for insomnia patients. Mental Health Matters.
660. Vilke, G. M., & Ly, B. T. (2022). Clinical Syndromes and Emergency Room Physician and Management Issues. CRC Press eBooks. https://doi.org/10.4324/9781315155159-1
661. Vitiello, B., Zuddas, A., & Masi, G. (2006). Pharmacologic treatment of children and adolescents with attention deficit hyperactivity disorder. CRC Press eBooks. https://doi.org/10.1201/b14454-11
662. Voon, V., Thomsen, T., Miyasaki, J. M., Souza, M. D., Shafro, A., Fox, S. H., Duff‐Canning, S., Lang, A. E., & Zurowski, M. (2007). Factors Associated With Dopaminergic Drug–Related Pathological Gambling in Parkinson Disease. Archives of Neurology. https://doi.org/10.1001/archneur.64.2.212
663. Vázquez, G., Forte, A., Camino, S., Tondo, L., & Baldessarini, R. J. (2017). Treatment implications for bipolar disorder co-occurring with anxiety syndromes and substance abuse. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198748625.003.0017
664. Walther, M., & Woods, D. W. (2010). Trichotillomania. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy1011
665. WASILEWSKI, H., Rímoli, C. F., STEFFEN, J. P., Gonçalves, T. L. D. B., MARQUES, L. D. B., & Belotto, L. F. D. S. (2023). Treatments for Idiopathic Sudden Hearing Loss: Literature Review. American Journal of Medical and Clinical Sciences. https://doi.org/10.33425/2832-4226/23015
666. Werf-Eldering, M. J. V. D., Schouws, S., Arts, B., & Jabben, N. (2012). [Cognitive dysfunction in bipolar disorder: determinants and functional outcome].. PubMed.
667. Wet, E. D. (2006). Dealing with traumatic events : social skills. SA pharmacist's assistant/South African pharmacist's assistant.
668. Wick, J. Y., & Zanni, G. R. (2011). Helping Those with Hoarding Behaviors. The Consultant Pharmacist. https://doi.org/10.4140/tcp.n.2011.458
669. Wiegant, V. M. (1991). [Stress].. PubMed.
670. Wilson, D. J. (1985). Experience with Drugs and Driving in Queensland, Australia. Medicine Science and the Law. https://doi.org/10.1177/002580248502500102
671. Wilson, D. S., & Nutt, P. D. J. (2013). Insomnia. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199674558.003.0003
672. Winters, K. C., & Ingwalson, A. (2022). Internalizing and Related Disorders. Oxford University Press eBooks. https://doi.org/10.1093/med-psych/9780190678487.003.0006
673. Winters, K. C., & Ingwalson, A. (2022). Substance Use Disorders. Oxford University Press eBooks. https://doi.org/10.1093/med-psych/9780190678487.003.0005
674. Wirz‐Justice, A. (2003). Chronobiology and mood disorders. Dialogues in Clinical Neuroscience. https://doi.org/10.31887/dcns.2003.5.4/awirzjustice
675. Wise, E., Lyketsos, C. G., & Onyike, C. U. (2018). Aggression and Violence. American Psychiatric Association Publishing eBooks. https://doi.org/10.1176/appi.books.9781615371990.jl06
676. Wise, R. A. (1982). Neuroleptics and operant behavior: The anhedonia hypothesis. Behavioral and Brain Sciences. https://doi.org/10.1017/s0140525x00010372
677. Wolf, B. C., & Griffiths, R. R. (1991). Physical dependence on benzodiazepines: differences within the class. Drug and Alcohol Dependence. https://doi.org/10.1016/0376-8716(91)90044-y
678. Wolff, A., Vanduynhoven, E., Kleef, M. V., Huygen, F., Pope, J. E., & Mekhail, N. (2011). 21. Phantom Pain. Pain Practice. https://doi.org/10.1111/j.1533-2500.2011.00454.x
679. Wolff, A., Vanduynhoven, E., Kleef, M. V., Huygen, F., Pope, J. E., & Mekhail, N. (2011). Phantom Pain. https://doi.org/10.1002/9781119968375.ch21
680. Wright, S. L. (2020). Benzodiazepine Withdrawal. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197517277.003.0008
681. Wyatt, J. P., Illingworth, R. N., Graham, C. A., Hogg, K., Clancy, M., & Robertson, C. E. (2012). Environmental emergencies. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199589562.003.0006
682. Yan, X. (2024). Research on the BCI Treatment and Inventions in ADHD. MedScien. https://doi.org/10.61173/a0jwjd65
683. Yersin, B. (1999). [Ambulatory management of alcohol withdrawal syndrome].. PubMed.
684. Yi, L. (2004). 负性强化与药物依赖. Zhonghua xingwei yixue yu naokexue zazhi. https://doi.org/10.3760/cma.j.issn.1005-8559.2004.04.060
685. Yorozuya, K., Kubo, Y., ASAOKA, Y., Hayashi, H., Fujita, T., & Hanaoka, H. (2024). A multimodal non‐pharmacological intervention for persons with dementia in nursing homes: a multicentre randomised controlled trial. Psychogeriatrics. https://doi.org/10.1111/psyg.13186
686. Young, E. (1990). The Role of Incest Issues in Relapse. Journal of Psychoactive Drugs. https://doi.org/10.1080/02791072.1990.10472547
687. Young, P., Finn, B. C., Bruetman, J. E., Pellegrini, D., & Kremer, A. (2010). [The chronic asthenia syndrome: a clinical approach].. PubMed.
688. Young, W. B. (2004). Clinical Science: Treatment of Medication Overuse Headache and Long‐term Outcome. Headache Currents. https://doi.org/10.1111/j.1743-5013.2004.10112.x
689. Yu, Y., & Gong, S.-P. (2008). Multiple organ supportive therapy for obstetric multiple organ dysfunction syndrome. https://doi.org/10.3321/j.issn:0376-2491.2008.11.003
690. Yudofsky, S. C., Silver, J., & Anderson, K. (2013). Aggressive Disorders. American Psychiatric Publishing eBooks. https://doi.org/10.1176/appi.books.9781585625154.da10
691. Yustiana, A. V., & Aryani, L. N. A. (2019). Gangguan psikotik akibat penggunaan ganja (cannabis): studi kasus. Medicina Journal. https://doi.org/10.15562/medicina.v50i2.123
692. Zalpuri, I., Matzke, M., & Joshi, S. V. (2024). Obsessive-Compulsive Disorder in Children and Adolescents: Early Detection in Primary Care Settings. PEDIATRICS. https://doi.org/10.1542/peds.2024-069121
693. Zarzycki, M., & Domitrz, I. (2019). Stimulation-induced side effects after deep brain stimulation – a systematic review. Acta Neuropsychiatrica. https://doi.org/10.1017/neu.2019.35
694. Zauner, J. (1978). [Psychosomatic aspects of adolescence].. PubMed.
695. Zawilska, J. B., & Tomaszewska, A. (2019). Psychoactive substances used to increase sexual activity: chemsex. Farmacja Polska. https://doi.org/10.32383/farmpol/116296
696. Zdybel, M., Rdzanek, B. J., & Skrzypek, W. (2025). OBSESSIVE COMPULSIVE DISORDER - A REVIEW OF TREATMENT METHODS. International Journal of Innovative Technologies in Social Science. https://doi.org/10.31435/ijitss.3(47).2025.3714
697. Zhao, H., Li, S., & Wang, Y. (2023). A case report of atypical sleep in an ischemic stroke patient with psychiatric symptoms caused by olanzapine. Frontiers in Neurology. https://doi.org/10.3389/fneur.2023.1266204
698. Zhu, X., Zhang, J., & Li, M. (2012). [Decreased sound tolerance and tinnitus].. PubMed.
699. Zoellner, L. A., Graham, B., & Bedard‐Gilligan, M. (2019). Trauma- and Stressor-Related Disorders. Routledge eBooks. https://doi.org/10.4324/9780429028267-10
700. Çorumlu, E. P., Aydın, O. Ö., Aydın, E. G. G., & Ulupınar, E. (2015). Effects of single-dose ketamine infusion on behavioral parameters and neuronal activation in the medial prefrontal cortex of juvenile rats exposed to prenatal stress. Anatomy (International Journal of Experimental and Clinical Anatomy). https://doi.org/10.2399/ana.15.027
701. Şengül, C., Özen, M., & Sunumu, O. (2010). Do Münchausen syndrome or malingering.